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Lin H. Taft 
STATISTICAL METHODS TO STUDY HETEROGENEITY OF TREATMENT 
EFFECTS 
Randomized studies are designed to estimate the average treatment effect (ATE) 
of an intervention. Individuals may derive quantitatively, or even qualitatively, different 
effects from the ATE, which is called the heterogeneity of treatment effect. It is important 
to detect the existence of heterogeneity in the treatment responses, and identify the 
different sub-populations. Two corresponding statistical methods will be discussed in this 
talk: a hypothesis testing procedure and a mixture-model based approach.  The 
hypothesis testing procedure was constructed to test for the existence of a treatment effect 
in sub-populations. The test is nonparametric, and can be applied to all types of outcome 
measures. A key innovation of this test is to build stochastic search into the test statistic 
to detect signals that may not be linearly related to the multiple covariates. Simulations 
were performed to compare the proposed test with existing methods. Power calculation 
strategy was also developed for the proposed test at the design stage. The mixture-model 
based approach was developed to identify and study the sub-populations with different 
treatment effects from an intervention. A latent binary variable was used to indicate 
whether or not a subject was in a sub-population with average treatment benefit. The 
mixture-model combines a logistic formulation of the latent variable with proportional 
hazards models. The parameters in the mixture-model were estimated by the EM 
algorithm. The properties of the estimators were then studied by the simulations. Finally, 
all above methods were applied to a real randomized study in a low ejection fraction 
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population that compared the Implantable Cardioverter Defibrillator (ICD) with 
conventional medical therapy in reducing total mortality. 
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CHAPTER 1. INTRODUCTION 
In clinical trials, it is common practice to report the average treatment effect 
(ATE) for the whole trial population. However, ATE may fail when different subgroups of 
patients have different treatment effects. It is widely accepted that individuals may derive 
quantitatively, or even qualitatively, different effects from the ATE. Detecting the 
heterogeneity of the treatment effects (HTE) is of increasing interests and crucial in 
evaluating and selecting treatments for individuals. For example, if a treatment is 
expensive, and may have adverse effects for some, we should obviously apply it only 
when it will improve the health outcome of interest. Our goal is to determine which 
patients will benefit from treatment and which not, so as to not do more harm than good.  
The first step toward the goal is to develop a test, which can detect if there are 
beneficial effects and harmful effects from the treatment compared to the control. In 
addition, the test may help with power calculations and further study design. As a second 
step, we want to develop models to identify who benefits from the treatment and who 
does not, and the estimated average treatment effect in different sub-populations. 
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1.1 A Non-parametric Statistical Test of Null Treatment Effect in Sub-Populations  
It is common that a medical intervention has a treatment benefit only for some 
patients in the intended patient population, whereas the rest do not derive a benefit and 
some are even harmed by the intervention.  
Intuitively, to test the interaction effects between the treatment and subgroup, one 
can either partition patients into subgroups, to test the treatment effect in each subgroup, 
or add treatment-covariate interaction terms in the multiple regression. However, there 
are a lot of problems with the simple subgroups analysis methods. Not only does multiple 
comparison inflate the type I error, and creates selection bias, but also each subgroup may 
have a limited sample size making the test unreliable.   
A lot of researchers have been working on improving the tests. There are 
generally two types of tests, one is to pre-specify a fixed number of subgroups before the 
statistical analysis, and another one is a post hoc subgroup search. Most publications in 
these two types heavily rely on model assumptions. However, it is hard to choose the 
right form of the interaction terms of the correct covariates, which substantially affects 
the study results. In this dissertation, we propose a non-parametric test with built-in 
stochastic search to avoid model assumptions and apply the test on a dataset with time-to-
event outcome. 
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1.2 Power Calculation for Study Design 
As a post hoc test, the main purpose of the test is to help guide study design in the 
future. With some knowledge on the HTE, we can design a study to achieve the desired 
power to detect HTE. In this dissertation, we try to give recommendations on the sample 
sizes in study designs under the assumption that the treatment effects are normally 
distributed. We also use some computational methods to help deal with some very 
complex formulations.  
 
1.3 Logistic-Cox Mixture Model 
Mixture models have been applied to different areas in survival analysis, such as 
competing risks, and cure rate analysis.  
In this dissertation, we develop the mixture model to model the heterogeneity of 
the treatment effect with the assumption that different groups have different average 
treatment effects. We focus on having only two sub-populations in this dissertation; one 
group of patients has beneficial effect from the treatment, whereas the other group has no 
effect or a harmful effect. We use constrains to separate the treatment effects into 
different ranges to create two groups, and calculate the posterior probability of each 
patient in each group to use as a weight to model patients in different groups with 
different survival models. The mixture model can be simply expanded to accommodate 
more sub-populations with different treatment effects, although more complex models 
may require more patient subjects to estimate. In addition, the constraints on different 
groups’ treatment effects can be modified depending on different characteristics for 
different disease and different clinical trials. 
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My dissertation contains three related topics on the heterogeneity of treatment 
effects. In chapter 2, we introduce a statistical procedure to test the null treatment effect 
in sub-populations, and to determine the existence of sub-populations that have treatment 
effects in possibly different directions. In chapter 3, Study design and power calculations 
for the detection of HTE using the procedure described in chapter 2 are discussed. In 
chapter 4, a mixture model is developed to identify sub-populations with treatment 
benefit. Conclusions and discussions are summarized in chapter 5.  
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CHAPTER 2. A NON-PARAMETRIC STATISTICAL TEST OF NULL TREATMENT 
EFFECT IN SUB-POPULATIONS 
2.1 Background 
Randomized clinical trials (RCTs) are designed to estimate the average treatment 
effect (ATE) in a well-defined population. However, ATE may not reflect the impact of 
the treatment on every subject in the trials. It is well recognized that a medical 
intervention may have treatment benefit for some patients but not for others[1, 2]. For 
example, genetic variation can lead to different drug responses even in a relatively 
homogeneous population meeting the entry criteria of an RCT. In the extreme case, a 
medical intervention can even worsen the intended efficacy endpoints for some patients.  
In addition, medical interventions are applied to more heterogeneous populations in the 
real world, where the heterogeneity in treatment effect is likely enhanced. In principle, 
there are three types of patients, those who benefit from, are not affected by, and are 
harmed by the intervention. We will call them the “beneficial group”, “neutral group” and 
“harmed group”. The ATE is a net effect of the treatment effect in the three groups. In 
some clinical trials, treatment effect can be ‘a mixture of substantial benefits for some, 
little benefit for many, and harm for a few’[3]. In this case, ATE is the net result of the 
competition of the three groups and the inferred ATE can be tremendously misleading for 
some patients. 
Heterogeneity in treatment effect (HTE) is usually detected through the test of the 
interaction between treatment arm indicatory and a covariate whose value defines sub-
populations. There are two types of interactions first introduced by Peto [4]: the 
qualitative interaction (QLI) and the quantitative interaction (QNI). Peto described QLI 
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as when the true treatment effects vary in direction among sub-populations, and he used 
QNI when variation is only in magnitude, but not in direction. Obviously, the existence of 
QLI is critical and the most detrimental, where a patient can be given a treatment 
considered to be effective based on ATE that will actually worsen the outcome. 
The caveats of existing approaches subgroup analysis have been discussed in 
multiple publications[5-7]. Specifically for the detection of HTE, conventional statistical 
tests of interaction terms usually rely on correct specification of a parametric or semi-
parametric model. This is a major limitation as the test is not very meaningful if the 
model is wrong.  
Gail and Simon (G&S) [8] developed a likelihood ratio test to detect  QLI in the 
setting of I fixed sub-populations. They defined two test statistics that summarize positive 
and negative standardized treatment differences over subgroups. The null hypothesis of 
consistent direction in treatment effect across the sub-populations is rejected if both 
statistics exceed critical values. Later Piantadosi and Gail (P&G)[9] proposed a 
standardized range test where the maximum and the minimum of the standardized 
treatment difference of each subgroup are test statistics. Li and Chan [10] proposed an 
extension to the range test to utilize all the observations rather than only use the max and 
min, to reach better power. Recently, Bayman et al. [11] proposed a method using Bayes 
factor to test for QLI when multiple subgroups were determined only by one variable.  
All above methods are designed for pre-specified sub-populations. Alternative 
approaches have been developed to search for sub-populations (e.g. identify QLI with 
variable selection). Bonetti and Gelber[12] discussed the subpopulation treatment effect 
pattern plots (STEPP) approach. In this approach, they defined overlapping 
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subpopulations that contain patients with increasingly larger (or smaller) value of a 
specific covariate, to explore the interaction between this covariate and the treatment 
effect. Chen et al. [13] proposed a Bayesian approach to search for qualitative 
interactions in a multiple regression setting with adaptive decision rules. Tian et al. 
[14]developed a simple modified covariate method to estimate the covariates and 
treatment interaction without the need of  main effect. Several tree-based methods were 
proposed to avoid the problem of incorrect model assumption, such as Virtual Twins [15] 
and Qualitative Interaction Trees (QUINT)[16].  
Motivated by the methods of G&S and P&G, in this chapter, we propose a non-
parametric test to test the sharp null hypothesis that the treatment has null effect on every 
sub-group in the setting of a large number of sub-groups defined by a set of covariates. 
We focus on RCTs with discrete covariates in this chapter, though the method can be 
directly extended to continuous covariates and observational studies (see Discussions). 
Our strategy for the construction of the test strikes a balance between sufficient sample 
size for informative accuracy and adequate account of subject characteristics for the 
detection of HTE. Specifically, the subgroups, defined later in Method section as cells, 
induce a large number of overlapping sub-populations by various combinations. Our 
strategy is to sample from the pool of sub-populations and then to apply G&S and P&G 
type approaches. A key innovation of our method is that stochastic search is built into the 
test statistic to detect signals that may not be detectable through parametric and semi-
parametric modeling.   
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In section 2, we introduce our method and how to construct the test statistics. The 
test is then applied on a real data example in section 3, followed by two simulations in 
section 4. We concluded the chapter with a discussion in section 5.  
 
2.2 Method 
2.2.1 Definitions and Hypothesis 
We focus on randomized clinical trials with one intervention arm and one control 
arm. Let ,, ,$, … , ,- denote the discrete baseline covariates. If each variable ,. has /. 
levels, then the covariate space can be divided in to ∏ /.-.1  unique cells that cannot be 
further divided. In other words, a cell is the smallest sub-population at which treatment 
effect can be evaluated non-parametrically. For example, if there are three binary baseline 
variables, then there are eight different cells. In real datasets, some cells may be empty 
and can be removed. Let 2 denote the number of cells with at least one subject in each 
treatment arm.  
Let 34 be the true treatment effect in cell 5 = 1,2, … , 2, where positive values of 34 represent treatment benefit and negative values of 34 represent treatment harm. A two-
sided null hypothesis is that there is no treatment effect in any cell, or 678: 34 = 0, 5 =1,2, … , 2. The corresponding alternative hypothesis is 68: 34 ≠ 0, for some 5 = 1,2, … , 2. 
For one-sided test of either benefit or harm, the null hypotheses are: 67@: 34 ≤ 0, 5 =1,2, … , 2 and 67B: 34 ≥ 0, 5 = 1,2, … , 2 respectively. Their corresponding alternative 
hypotheses are: 6@: 34 > 0, for some 5 = 1,2, … , 2 and 6B: 34 < 0, for some 5 =1,2, … , 2.     
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2.2.2 Test Statistics 
In Gail and Simon[8], the estimated treatment effect 3F4 was assumed to be 
independent and normal distributed with mean 34, and known variance G4$. The two-sided 
null hypothesis was stated as 67$: H ∈ 0J ∪ 0L, where HM = N3, 3$, … , 3OP, 0J =NH: 34 ≥ 0 Q55 5P and 0L = NH: 34 ≤ 0 Q55 5P. Their two-sided null hypothesis is different 
than the one in this chapter, it is hypothesizing either all cells have benefit or no 
treatment effect, or all cells have harmful or no treatment effect. In other words, it is 
testing the existence of QLI. They provided R level critical values S$T for the likelihood 
ratio test, to reject 67$ if both ∑ V3F4$/G4$X3F4 > 0YO41 > S$T and ∑ V3F4$/O41
G4$X3F4 < 0Y > S$T. Here X(.  is an indicator function, makes the summations over all 
positive 3F4’s in the first expression, and over all negative 3F4’s in the second expression. 
The standardized range test by P&G rejects 67$ at level R if both ZQ,V3F4/G4Y >
S$T[  and Z\]V3F4/G4Y < −S$T[ , where S$T[  are R level critical values provided by them. 
Although in principle we can apply approaches similar to G&S and P&G to test 
678, 67@ or 67B, there are some major limitations due to the small sample sizes in each cell. 
First, conventional asymptotic properties do not apply to cell-specific statistic and the 
critical values cannot be derived from asymptotic distributions. Second, in the extreme 
case, some cells may only have one data point in each arm, which makes the calculation 
of G&S and P&G statistic highly unreliable. Third, the test statistic tends to have high 
variation leading to reduced power. To address these issues, we propose a non-parametric 
permutation test that target on stochastic sub-populations that are the union of some cells. 
To create a stochastic sub-population, we select each cell with a pre-specified 
probability _. In the earlier example with eight cells, if _ is assumed to be 0.25, then on 
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average, a total of two cells may be selected to form a sub-population. Choosing the right 
_ is crucial to the proposed test. If _ is too large, too many cells will be selected, then 
different types of subgroups (i.e. beneficial group, harmed group, etc.) may likely to be 
mixed together causing the dilution effect. If _ is too small, then the sample size of the 
sub-population may not be large enough. Next, ` sub-populations can be drawn 
independently. ` is also important since enough variety of sub-populations need to be 
drawn to be able to detect treatment signals.  
For a particular sub-population \, a test statistic ab can be calculated depending on 
the type of outcomes, which represents the magnitude and direction of the treatment 
effect in sub-population \. In our set-up, positive sign of Zi corresponds to beneficial 
effect and the negative sign of Zi corresponds to harmful effect.  For the k sub-
populations, if one of them has an extreme ab or the average of ab’s with the same sign 
are extreme, then the null hypothesis is rejected. Thus, the  statistics for beneficial effect 
can be defined as either 
cd = max(ab, 
or  
 c8 = g max(ab, 0`hb1 . 
Similarly, the harm statistics can be defined as 
id = min(ab kl i8 = g min(ab, 0`hb1 . 
 
We call tests based on  cd or id the one-sided extreme value test, and tests based 
on both of them the two-sided extreme value test. Similarly, one or two-sided average 
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value test can be constructed using c8 and i8. The rationale of our test statistics is that if 
we explore a large number (`) of sub-populations, we will have better chance to detect 
the existence of treatment benefit/harm in some people. 
For binary outcomes, let _ be the proportion of patients with favorable outcome. 
A standard choice of ab is  
ab = _̂b − _̂b7cnob  
cnob = p_̂b(1 − _̂b q 1]b + 1]b7st7.u 
where _b, _b7 are the sample proportions, and ]b, ]b7 are the sample sizes for treatment 
and control groups respectively. Standard error (cnb) can be calculated using a pooled 
sample proportion (_b). 
In the case of a continuous outcome, the conventional T statistic ab can be used: 
ab = vwb − vwb7xyb$]b + yb7$]b7
, 
where vwb and vwb$ are the sample means, yb$  and yb7$  are the sample variances of the two 
groups. 
For time-to-event outcome, a cox proportional hazard model can be fitted with 
treatment as the explanatory variable in the model. For the \th sub-population, the hazard 
function ℎb({|} given } at time { can be written as: ℎb({|} = ℎb({exp (il{ ∗ bM 
where ℎb({ is the baseline hazard function at time { for the \th sub-population. 
In this case, ab is  
  12
 
ab = − bMy(bM 
 
2.2.3 Null distribution of c(3 and i(3 
Permutation technique can be used for the construction of the null distribution of 
the test statistics. Here we are using cd to illustrate. Under our null hypothesis, the 
treatment and control do not differ on the outcome (i.e. the outcome is independent of 
treatment assignment). When we permute the treatment assignment  times, we therefore 
create  datasets of the possible alternative treatment assignments we could have had, 
and calculate  possible cd∗ (i.e. cd∗, c$d∗,…, cd∗). When  is a fairly large number, we 
can estimate the empirical null distribution of cd, and calculate the R level critical values 
based on this distribution. 
For the extreme value tests: 
1. Reject 678 if either cd > S$Td  or id < S$TMd; 
2. Reject 67@ if cd > STd; 
3. Reject 67B if id < STMd. 
where R level critical values S$Td  and STd  are defined as (1 − R/2) and (1 − R) 
percentile of cd∗ respectively. Similarly, R level critical values S$TMd and STMd are defined 
as R/2 and R percentile of id∗ correspondingly. The rejection rules are followed in the 
same way for the average value tests.  
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2.3. Application to Madit II data 
We apply these two tests to Multicenter Automatic Defibrillator Implantation Trial 
II (MADIT II)[17, 18]. MADITII ran from 1997 to 2001, in which1,232 patients with a 
prior myocardial infarction and a left ventricular ejection fraction of 0.3 or less were 
recruited. Patients were randomly assigned in 3:2 ratio to receive an implantable 
cardioverter defibrillator (ICD) (n=742) or conventional medical therapy (n=490). 
Patients were followed until death or end of study; the primary outcome is time to all-
cause mortality.  
Five binary risk factors have been identified as potential effect modifiers in a 
previous study [18]. They are New York Heart Association functional class (NYHA) > II, 
age > 70 years, blood urea nitrogen (BUN) > 26 mg/dl, QRS duration > 0.12 s, and atrial 
fibrillation. 112 patients with missing values in any of the five risk factors were excluded. 
Summary statistics on these five variables are included in Table 1.  
Table 1 Summary Statistics: Five Risk Factors of the 1232 Patients 
Characteristic 
Defibrillator 
Group 
n=674 
Conventional-
Therapy Group 
n=446 
Age (yr) > 70, n (%) 195 (29) 137 (31) 
NYHA Functional Class >II, n 
(%) 
202 (30) 123 (28) 
Blood Urea Nitrogen>26mg/dl, n 
(%) 
181 (27) 133 (30) 
Atrial Fibrillation, n (%) 57 (8) 38 (9) 
QRS interval≥0.12 sec, n (%) 233 (35) 134 (30) 
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32 cells were constructed based on these binary covariates; the size of each cell is 
shown in Table 2. Cell 28 was deleted in the simulation and analysis since both patients 
were in the treatment arm. 
Table 2 The Information of the 32 Cells Based on the Five Risk Factors 
Cell 
Number 
No. of Risk 
Factors 
Size Cell 
Number 
No. of Risk 
Factors 
Size 
1 0 346 17 3 47 
2 1 16 18 3 3 
3 1 99 19 3 9 
4 1 47 20 3 31 
5 1 72 21 3 6 
6 1 96 22 3 56 
7 2 6 23 3 24 
8 2 5 24 3 4 
9 2 35 25 3 17 
10 2 10 26 3 22 
11 2 58 27 4 6 
12 2 43 28 4 2 
13 2 7 29 4 3 
14 2 40 30 4 3 
15 2 48 31 4 24 
16 2 23 32 5 4 
 
The ` and _ pair was selected to provide the best power in the MaditII data. The 
explanation is provided in section 4. Specifically, _ = 0.5 and ` = 100 were used for the 
two-sided extreme value test, while _ = 0.1 and ` = 300 were used for the two-sided 
average value test. For one-sided tests, slightly different pairs were chosen. The selected 
pair of ` and _ for each test, and the corresponding p-values are shown in Table 3. 
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678 and 67@ were both rejected using extreme value tests and average value tests 
(p<0.0001). However, 67B was not rejected with p-values 0.5933 and 0.6483 for the one-
sided extreme value test and average value test. 
Table 3 The Pair of _ and ` Selected from the Simulations 
 
Test Statistics   p-value 
Two-sided cdand id 0.1 300 <0.0001 
 
c8 and i8 0.5 100 <0.0001 
One-sided 
    
Test for beneficial 
effect 
cd 0.5 500 <0.0001 
 
c8 0.1 300 <0.0001 
Test for harmful 
effect 
id 0.3 100 0.5933 
 
i8 0.5 500 0.6483 
 
2.4. Simulation 
Two simulations were carried out. Simulation one is to find a set of ` and _ that 
has the most power under each simulation setting for each method, and to compare the 
power using the selected (`∗, _∗ in the proposed methods with some existing tests. Since 
data were simulated based on the Multicenter Automatic Defibrillator Implantation Trial 
II (MADIT II)[17, 18], (`∗, _∗ were applied to test the existence of the ‘benefit group’ 
and ‘harm group’ in MADIT II, as described in the previous section. 
To better understand the reasons behind the choice of (`∗, _∗, we conducted 
simulation two. Different factors can affect the selection, so we simulated datasets with 
equal-sized cells to eliminate the effect from the unequal sample size.  
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All the parameter values used in the simulations are shown in Table 4. 
Table 4 The Parameter Values in the Simulations 
 
        
Simulation One-A 0.5 0.7 0.4 0.5 0.6 0.5 -0.4 NA 
Simulation One-B 0.5 0.7 0.4 0.5 0.6 0.5 -0.4 0.4 
Simulation Two-A 0.5 0.2 0.4 0.5 0.6 0.5 -0.4 NA 
Simulation Two-B 0.5 0.2 0.4 0.5 0.6 0.5 -0.8 0.8 
Simulation Two-C 0.5 0.2 0.4 0.5 0.6 0.5 -0.4 0.4 
 
2.4.1 Simulation One 
From the past papers [17-19], we believe the patient population in MADIT II 
consist at least ‘benefit group’ and ‘neutral group’, and we suspect the existence of a 
‘harm group’. As a result, we ran two simulation settings, one is to create a population 
consist with ‘benefit group’ and ‘neutral group’, to apply and examine the one-sided tests. 
The other setting is to imitate a patient population with all three types of patients (‘benefit 
group’, ‘harm group’ and ‘neutral group’), to utilize and assess both the one-sided and 
two-sided tests. In both simulation settings, 1000 Monte Carlo datasets were generated 
based on MADIT II data.  
2.4.1.1 Null and Alternative Hypotheses 
Three sets of hypotheses mentioned in section 2 were used in the simulations: 
1. 678: 34 = 0, 5 = 1,2, … , 2; 68: 34 ≠ 0, for some 5 = 1,2, … , 2 
2. 67@: 34 ≤ 0, 5 = 1,2, … , 2; 6@: 34 > 0, for some 5 = 1,2, … , 2 
3. 67B: 34 ≥ 0, 5 = 1,2, … , 2; 6B: 34 < 0, for some 5 = 1,2, … , 2 
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2.4.1.2 Simulation One-A: 
In this simulation, to produce the population with benefit and no effect sub-
groups. The simulation setting is as follows: 
 Benefit cells: Patients had QRS duration > 0.12s (16 cells, 367 patients); 
 No treatment effect cells: the rest of the patients;  
 Time to death was assumed to have exponential distribution with rate ; 
 The five baseline characteristic variables from MADIT II data were used to 
generate the rate:  = ℎ7exp ( ∗ X(6 > XX + $ ∗ X(Q > 70 +  ∗X( > 26 +  ∗ X(c > 0.12 + u ∗ X(Q{l\Q5 \ {\55Q{\k] + ¡¢ ∗X(]\{ /55y ∗ il{  
 Censoring time is uniformly distributed between 2 to 4 years. 
Powers were calculated for both one-sided extreme value test and the average 
value test with ` = 100,200,300,400,500 and with _ = 0.1,0.2,…,0.5, to search for the 
pair that gives the best power. Then compare these two tests using their corresponding 
optimal pair of ` and _ with the following existing methods: 
1. The overall log-rank test (presented as ‘Logrank Test’ in the result Table); 
2. The true Cox Proportional Hazard models;  
3. One-sided likelihood ratio test by G&S[8]; 
4. One-sided range test by P&G[9]. 
2.4.1.3 Simulation One-B: 
The modification setting one-B from one-A is the harm cells were created, besides 
the benefit and no effect cells. The results were compared with the same existing methods 
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as in simulation one-A, with additional comparison with two coxPH models fitted using 
wrong model assumptions. 
The simulation setting is as follows: 
 Benefit cells: Patients had QRS duration > 0.12s(16 cells, 367 patients); 
 Harm cells: Patients had NYHA ≤ II, age ≤ 70, BUN ≤ 26 mg/dl, QRS duration 
≤ 0.12s (2cells, 362 patients);; 
 No treatment effect cells: the rest of the patients; 
 The time to death was assumed to have exponential distribution with rate $; 
 Similarly, the five baseline characteristic variables from MADIT II data were used 
to generate the rate: $ = ℎ7 exp( ∗ X(6 > XX + $ ∗ X(Q > 70 +  ∗X( > 26 +  ∗ X(c > 0.12 + u ∗ X(Q{l\Q5 \ {\55Q{\k] + ¡¢ ∗X(]\{ /55y ∗ il{ + £¡ ∗ X(ℎQlZ /55y ∗ il{;  
 Simulated time was censored uniformly between 2 to 3 years. 
The two wrong models were fitted as follows: 
Wrong Cox Proportional Hazard Model 1:  
¤ = ℎ7 exp( ∗ X(6 > XX + $ ∗ X(Q > 70 +  ∗ X( > 26 + ∗ X(c > 0.12 + u ∗ X(Q{l\Q5 \ {\55Q{\k] +  ∗ il{ + ¥¦¢ ∗X(Q > 70 ∗ il{;  
Wrong Proportional Hazard Model 2: Five baseline variables + Trt 
¤$ = ℎ7 exp( ∗ X(6 > XX + $ ∗ X(Q > 70 +  ∗ X( > 26 + ∗ X(c > 0.12 + u ∗ X(Q{l\Q5 \ {\55Q{\k] +  ∗ il{. 
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For the wrong Cox Proportional Hazard models, Wald tests were used to test the 
hypotheses. The null hypotheses for the Wald tests are  = ¥¦¢ = 0 for wrong 
model 1, and  = 0 for wrong model 2. 
2.4.1.4 Type I error rate 
To examine the Type I error, no treatment effect was assumed, simulation data 
were constructed the same as simulation one-B with ¡¢ = £¡ = 0. The type I errors 
were calculate for the two-sided extreme test with ` = 100,200,300,400,500 and with 
_ = 0.1,0.2,…,0.5 using 1000 Monte Carlo datasets. The results are shown in Table 5. 
Several combination of ` and _ were used to spot-check the type I error for the rest of the 
proposed methods. The results were all around 0.05. 
Table 5 The Type I Error Results of Two-Sided Test with cd and id 
  
 
  
100 200 300 400 500 
 
0.1 0.051 0.048 0.052 0.040 0.049 
0.2 0.050 0.046 0.062 0.052 0.053 
0.3 0.056 0.049 0.043 0.062 0.044 
0.4 0.058 0.048 0.050 0.052 0.050 
0.5 0.062 0.050 0.048 0.038 0.045 
 
2.4.1.5 Results 
 Simulation One-A 
The power for each combination of ` and _ for one-sided extreme value test and 
average value test was calculated as shown in Tables 6 and 7 respectively. In Table 6, 
when _ increases from 0.1 to 0.5, the power gets larger, and reaches the maximum at 
0.694 when (`∗, _∗ = (400,0.5). On the contrary, in Table 7, the power gets smaller 
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when _ increases from 0.1 to 0.5, and (`∗, _∗ = (500,0.1) are found to give the largest 
power 0.719.  
Table 6 The Power to detect existence of sub-populations with treatment benefit under 
simulation One-A using one-sided extreme value test cd. 
  
 
  
100 200 300 400 500 
 
0.1 0.442 0.468 0.429 0.458 0.452 
0.2 0.518 0.556 0.557 0.569 0.537 
0.3 0.624 0.616 0.609 0.628 0.647 
0.4 0.633 0.637 0.662 0.664 0.653 
0.5 0.659 0.675 0.67 0.694 0.673 
 
Table 7 The Power to detect existence of sub-population with treatment benefit under 
simulation One-A using one-sided average value test with c8 
     
    100 200 300 400 500 
 
0.1 0.648 0.71 0.711 0.709 0.719 
0.2 0.632 0.664 0.691 0.665 0.668 
0.3 0.619 0.61 0.611 0.632 0.649 
0.4 0.57 0.578 0.565 0.551 0.589 
0.5 0.535 0.511 0.537 0.524 0.538 
 
Table 8 Power comparisons for simulation One-A 
One-sided 
Extreme value 
test k=400 
p=0.5 
One-sided 
Range 
Test 
One-sided 
Average 
value test 
k=500 p=0.1 
One-
sided LR 
Test 
Logran
k Test 
True 
Model 
0.694 0.346 0.719 0.669 0.147 0.950 
 
  21
 
The comparisons of the powers of different methods are shown in Table 8. The 
one-sided extreme value test is clearly better than its P&G counterpart (power = 0.694 vs 
0.346). In addition, the one-sided average value test performs better than the one-sided 
G&S test (power = 0.719 vs 0.669). Overall, both of the proposed one-sided tests 
achieved much better power than the logrank test, and the average value test is slightly 
better than the extreme test.  
Simulation One-B 
The power follows similar trend for the two-sided test when _ changes. The 
power reaches 0.839 when (`∗, _∗ = (100,0.5) for the two-sided extreme value test, and 
0.623 when (`∗, _∗ = (300,0.1) for the two-sided average value test. (Table 9 and Table 
10) 
Table 9 The Power to detect existence of sub-population with treatment benefit under 
simulation One-B using the two-sided extreme value test 
     
    100 200 300 400 500  0.1 0.72 0.719 0.71 0.708 0.715 
0.2 0.763 0.749 0.76 0.783 0.763 
0.3 0.83 0.795 0.808 0.809 0.822 
0.4 0.823 0.801 0.815 0.828 0.818 
0.5 0.839 0.822 0.829 0.82 0.827 
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Table 10 The Power to detect existence of sub-population with treatment benefit under 
simulation One-B using the two-sided average value test 
     
    100 200 300 400 500  0.1 0.542 0.61 0.623 0.597 0.601 
0.2 0.503 0.5 0.537 0.536 0.561 
0.3 0.483 0.479 0.467 0.468 0.488 
0.4 0.384 0.362 0.368 0.394 0.382 
0.5 0.313 0.28 0.274 0.285 0.297 
 
It is interesting that in the one-sided extreme value test and average value test, _ 
were selected the same as the corresponding two-sided tests, i.e. _ = 0.5 for the one-
sided extreme value test and _ = 0.1 for the one-sided average value test. One the other 
hand, when test for harmful effect, _ = 0.3 and _ = 0.5 were chosen for id and i8 
respectively (Table 11-14). It may be because there are more cells that have beneficial 
effect than harmful effect, as a result, _ for the two-sided tests are influenced by the one-
sided test for beneficial effect.  
Table 11 The Power to detect existence of sub-population with treatment benefit under 
simulation One-B using the one-sided extreme value test with cd 
      
    100 200 300 400 500  0.1 0.427 0.459 0.451 0.458 0.451 
0.2 0.503 0.529 0.534 0.568 0.544 
0.3 0.614 0.593 0.606 0.61 0.638 
0.4 0.623 0.625 0.641 0.664 0.647 
0.5 0.652 0.655 0.66 0.68 0.684 
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Table 12 The Power to detect existence of sub-population with treatment benefit under 
simulation One-B using the one-sided extreme value test with id 
     
    100 200 300 400 500  0.1 0.721 0.711 0.722 0.686 0.709 
0.2 0.747 0.729 0.719 0.734 0.728 
0.3 0.751 0.734 0.733 0.738 0.733 
0.4 0.731 0.724 0.73 0.744 0.735 
0.5 0.691 0.735 0.702 0.729 0.73 
 
Table 13 The Power to detect existence of sub-population with treatment benefit under 
simulation One-B using the one-sided average value test with c8 
     
    100 200 300 400 500  0.1 0.548 0.616 0.624 0.601 0.614 
0.2 0.487 0.489 0.52 0.528 0.544 
0.3 0.417 0.424 0.428 0.417 0.452 
0.4 0.31 0.291 0.304 0.313 0.295 
0.5 0.203 0.171 0.178 0.176 0.171 
 
Table 14 The Power to detect existence of sub-population with treatment benefit under 
simulation One-B using the one-sided average value test with i8 
     
    100 200 300 400 500  0.1 0.175 0.151 0.143 0.136 0.137 
0.2 0.293 0.27 0.316 0.302 0.304 
0.3 0.386 0.368 0.383 0.394 0.383 
0.4 0.377 0.372 0.393 0.388 0.375 
0.5 0.371 0.36 0.371 0.371 0.395 
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The comparisons of the powers of different methods in this setting are shown in 
Table 15. Different from Table 8, methods using the extreme values (extreme value test 
and P&G range test) are in general better than using the average values, although they are 
all better than the logrank test, and the coxPH models with incorrect assumptions. 
Table 15 Power comparisons for simulation One-B 
Two-sided 
Extreme value test 
k=100 p=0.5 
Range Test Two-sided 
Average value test 
k=300 p=0.1 
LR Test 
0.839 0.726 0.623 0.559 
Logrank Test Wrong Model 1 Wrong Model 2 True Model 
0.130 0.297 0.047 Close to 1 
 
2.4.2 Simulation Two  
In this simulation section, the focus is to better understand the nature of choosing 
the set of ` and _ using the two sets of test statistics. 32 cells with equal number of 
patients were generated in three different settings. Powers were calculated in these 
settings for all proposed tests with ` = 100, 200, …, 500 and _ = 0.1, 0.2, … , 0.5, to 
study which pair gives the best power, and to summarize any patterns. 
2.4.2.1 Null and Alternative Hypotheses 
Two sets of hypotheses were used for this section: 
67@: 34 ≤ 0, 5 = 1,2, … , 2; 6@: 34 > 0, for some 5 = 1,2, … , 2 67B: 34 ≥ 0, 5 = 1,2, … , 2; 6B: 34 < 0, for some 5 = 1,2, … , 2 
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2.4.2.2 Simulation Two-A 
 Five binary baseline characteristic variables X, X$,…, Xu were generated to create 
32 cells with equal number of patients; 
 Treatment control ratio is 1:1 in each cell; 
 Benefit cells: ]¡¢£¢§b out of 32 cells were randomly selected to be cells 
benefitting from the treatment in each simulated Monte Carlo dataset ]¡¢£¢§b =
4,8,16; 
 No treatment effect cells: the rest of the patients; 
 Time to death was assumed to have exponential distribution with rate ; 
  = ℎ7 exp( ∗ X + $ ∗ X$ +  ∗ X +  ∗ X + u ∗ Xu + ¡¢ ∗X(]\{ /55y ∗ il{;  
 Simulated time was censored uniformly between 1 to 2 years. 
2.4.2.3 Simulation Two-B 
 Five binary baseline characteristic variables were generated to create 32 cells with 
equal number of patients; 
 Treatment control ratio is 1:1 in each cell; 
 Benefit cells: ]¡¢£¢§b out of 32 cells were randomly selected to be benefit cells in 
each Monte Carlo dataset ]¡¢£¢§b = 4,8,12; 
 Harm cells: ].¥¨ out of 32 cells were randomly selected to be benefit cells in 
each Monte Carlo dataset (].¥¨ = 4 
 No treatment effect cells: the rest of the patients; 
 The time to death was assumed to have exponential distribution with rate ; 
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  = ℎ7 exp( ∗ X + $ ∗ X$ +  ∗ X +  ∗ X + u ∗ Xu + ¡¢ ∗X(]\{ /55y ∗ il{ + £¡ ∗ X(ℎQlZ /55y ∗ il{;  
 Simulated time was censored uniformly between 1 to 2 years. 
2.4.2.4 Simulation Two-C 
 Different ¡¢, £¡ (with smaller absolute values compare to the fourth simulation) 
were used to calculate rate u; 
 Other settings were the same as the fourth simulation setting. 
2.4.2.5 Results 
Simulation Two-A 
The power results of the one-sided tests using cd and c8 with ]¡¢£¢§b = 4,8,16 
are presented in Table 16 to Table 21 respectively. Similarly to the one-sided test results 
in simulation one-A, testing using c8 has increasing power when _ decreases from 0.5 to 
0.1; on the other hand, testing using cd has increasing power when _ increases from 0.1 
to 0.5, for ]¡¢£¢§b = 8,16. For ]¡¢£¢§b = 4 using cd, however, power increases and 
reach the maximum at _∗ = 0.4, and starts to decrease. There is no noticeable pattern of 
power change when ` changes.   
_∗ = 0.1 was chosen for all the scenarios using c8, this makes sense since when 
using the average positive (or average negative), the more sub-populations have only 
beneficial (or harm) effects, the better the signal can be intensified. So smaller _ and 
larger ` are the top pick as in the simulation results. 
 
When using cd, things are a little bit different, since there is no harm cell to pull 
the beneficial cell into the opposite direction, and we are using a fairly small ` (compare 
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to the large number of possible combination of subpopulations), we are trying to find a 
balance between choosing a larger _∗ to provide a bigger sub-population with a better 
chance of more beneficial cells being selected into each sub-population, and choosing a 
small enough _∗, so not too many no treatment effect cells are included in each sub-
population. As a results, _∗ = 0.5 were chosen for ]¡¢£¢§b = 8, and _∗ = 0.4 were 
chosen for ]¡¢£¢§b = 4. 
Table 16 The Power to detect existence of sub-population with treatment benefit under 
simulation Two-A with ]¡¢£¢§b = 16 using the one-sided extreme value test with cd 
     
    100 200 300 400 500  0.1 0.6 0.626 0.612 0.625 0.629 
0.2 0.747 0.756 0.755 0.75 0.766 
0.3 0.802 0.806 0.833 0.808 0.839 
0.4 0.835 0.845 0.852 0.847 0.855 
0.5 0.855 0.868 0.878 0.856 0.877 
 
Table 17 The Power to detect existence of sub-population with treatment benefit under 
simulation Two-A with ]¡¢£¢§b = 8 using the one-sided extreme value test with cd 
     
    100 200 300 400 500  0.1 0.307 0.297 0.309 0.324 0.314 
0.2 0.333 0.391 0.389 0.393 0.361 
0.3 0.383 0.39 0.404 0.433 0.41 
0.4 0.42 0.412 0.427 0.445 0.453 
0.5 0.437 0.43 0.43 0.454 0.452 
Table 18 The Power to detect existence of sub-population with treatment benefit under 
simulation Two-A with ]¡¢£¢§b = 4 using the one-sided extreme value test with cd 
     
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    100 200 300 400 500  0.1 0.144 0.149 0.168 0.14 0.186 
0.2 0.149 0.197 0.175 0.2 0.172 
0.3 0.176 0.183 0.177 0.214 0.176 
0.4 0.168 0.186 0.207 0.214 0.19 
0.5 0.158 0.189 0.205 0.204 0.21 
 
Table 19 The Power to detect existence of sub-population with treatment benefit under 
simulation Two-A with ]¡¢£¢§b = 16 using the one-sided extreme value test with cd 
     
    100 200 300 400 500  0.1 0.879 0.891 0.896 0.903 0.89 
0.2 0.874 0.903 0.882 0.872 0.89 
0.3 0.855 0.865 0.884 0.89 0.882 
0.4 0.853 0.881 0.885 0.88 0.875 
0.5 0.852 0.879 0.882 0.875 0.873 
 
Table 20 The Power to detect existence of sub-population with treatment benefit under 
simulation Two-A with ]¡¢£¢§b = 8 using the one-sided extreme value test with cd 
     
    100 200 300 400 500  0.1 0.446 0.456 0.463 0.449 0.447 
0.2 0.384 0.433 0.445 0.447 0.442 
0.3 0.436 0.422 0.42 0.439 0.428 
0.4 0.42 0.434 0.424 0.438 0.443 
0.5 0.409 0.433 0.424 0.431 0.441 
 
Table 21 The Power to detect existence of sub-population with treatment benefit under 
simulation Two-A with ]¡¢£¢§b = 4 using the one-sided extreme value test with cd 
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     
    100 200 300 400 500  0.1 0.18 0.195 0.227 0.211 0.206 
0.2 0.186 0.183 0.18 0.194 0.187 
0.3 0.17 0.172 0.171 0.194 0.181 
0.4 0.169 0.17 0.187 0.189 0.187 
0.5 0.159 0.166 0.188 0.183 0.183 
 
Simulation Two-B and Two-C 
Results in simulation two-B and two-C have very similar characteristics in terms 
of _, except the power in two-C is in general smaller due to smaller effects were used, so 
we are only showing results for simulation two-B here. A table summarizing the selected 
(_∗, `∗) and power can be found in Table 22.  
For one-sided tests using c8 and i8, and id, _∗ = 0.1 was chosen for all the 
scenarios (]¡¢£¢§b = 4,8,12, ].¥¨ = 4). It is proven again, for the average value test, 
smaller _ is the better choice.  
For one-sided tests using cd, _∗ = 0.1, 0.3, 0.4 were chosen for ]¡¢£¢§b = 4,8,12 
respectively (].¥¨ is always 4). It seems that _∗ is chosen so that one of the sub-
populations can be formed by just the 12 (or 8, or 4) beneficial cells. Similarly, when 
using id, ideally _∗ should be selected to form a sub-population with the 4 harm cells, 
and _∗ = 0.1 was indeed chosen. 
 
  
  30
 
Table 22 The power results of one-sided tests using cd, id, c8, and i8 and the 
corresponding chosen _ and ` 
 ©ª «ª ©¬ «¬ 
 Scenario ]¡¢£¢§b = 4 ].¥¨ = 4 ]¡¢£¢§b = 4 ].¥¨ = 4 ]¡¢£¢§b = 4 ].¥¨ = 4 ]¡¢£¢§b = 4 ].¥¨ = 4 _∗ 0.1 0.1 0.1 0.1 `∗ 500 500 100 100 
Power 0.536 0.543 0.237 0.136 
 Scenario ]¡¢£¢§b = 8 ].¥¨ = 4 ]¡¢£¢§b = 8 ].¥¨ = 4 ]¡¢£¢§b = 8 ].¥¨ = 4 ]¡¢£¢§b = 8 ].¥¨ = 4 _∗ 0.3 0.1 0.1 0.1 `∗ 500 500 400 200 
Power 0.891 0.526 0.789 0.018 
 Scenario ]¡¢£¢§b = 12 ].¥¨ = 4 ]¡¢£¢§b = 12 ].¥¨ = 4 ]¡¢£¢§b = 12 ].¥¨ = 4 ]¡¢£¢§b = 12 ].¥¨ = 4 _∗ 0.4 0.1 0.1 0.1 `∗ 400 500 400 100 
Power 0.996 0.48 0.991 0.001 
 
2.5. Discussion 
Why non-parametric is good? Methods require some assumption of a model. 
Modeling of interactions between covariates and treatment indicator faces challenges. A 
major one is choosing the correct covariates in the right forms for the interaction terms, 
which heavily affects the results. Even if the terms of interactions are linear, the orders of 
the terms are still need to be determined.[19]   
In this chapter, we proposed a test that has a stochastic search built into the test 
statistic to detect signals that may not be linearly related to the multiple covariates. The 
one-sided and two-sided extreme value tests are based on the strongest positive and 
negative signals, while one-sided and two-sided average value tests are based on the 
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average positive and negative signals. The choice for the pair of ` and _ in the stochastic 
search are essential to this test.  
The choice of ` and _ has a major impact on the power of the test. Our simulation 
studies suggest that larger values of ` in general leads to better power or at least not far 
off the optimal power. The choice of parameter _ depends on the method. For the average 
value tests, smaller _ such as 0.1 is recommended. For the extreme value tests, it depends 
on the number of cells that have benefit (harmful) effect. When both benefit and harm 
groups exist, the optimal _∗ can be roughly estimated by  
{ℎ ]­Z l k  ]\{ (ℎQlZ­5 /55y ® {ℎ {k{Q5 ]­Z l k /55y. 
To construct the cells, we need non-missing clinical meaningful covariates. In this 
paper, we focused on RCTs with discrete covariates. To use the continuous covariates, 
they can be discretized by a series of the thresholds. The proposed methods can also be 
directly applied in observational studies, after the standard procedure to adjust for 
confounding variables before analyzing an observational study. 
Although the harmful effect was not detected for ICD using the MADIT-II data, 
Shen et al(ref) showed that 4-12% may actually be harmed  by an ICD in terms of two-
year survival after ICD implantation.  The difference is due to the fact that the current test 
cannot detect heterogeneity within a cell. In other words, if some patients in a cell is 
actually harmed by the ICD, such an effect may be masked if others in the same cell 
benefit from the ICD.   
The proposed tests in this chapter can serve as a first-line procedure to protect 
against false discoveries of benefit and harm. In next chapter, we apply this test to help 
calculate power and benefit study design. Our next step is to develop models to identify 
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who benefit from the ICD and who do not, and the estimated average treatment effect in 
different sub-populations.  Identification of sub-populations with treatment benefit or 
harm and estimation of treatment effect in sub-populations is an active research area[20-
24]. Nevertheless, active search is prone to selection bias and inflation of the probability 
of false positives. Our test can serve as a gatekeeping procedure to prevent false positives.   
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CHAPTER 3. POWER CALCULATION FOR STUDY DESIGN 
3.1 Background 
As a post hoc test, the main purpose of the test is to help guide study design in the 
future. With some knowledge on the HTE, we can design a study to achieve desired 
power to detect HTE. In this chapter, the treatment effects are under normal distribution. 
Normal approximation and central limit theorem were used in the formulation. Some 
computational methods were used to help deal with some very complex formulation. In 
section 2, we introduce different theoretical methods to calculate power with different 
parameter settings using cd and c8. Then the simulations are done to discover how the 
power changes when each parameter changes in the test, and to check the performance of 
the theoretical results by checking the results between the powers calculated by theory 
and by simulation in section 3. We concluded this chapter with a discussion in section 4.  
 
3.2 Method 
As mentioned in chapter two, there are two sets of test statistics: the maximum, 
minimum test statistics (cd = max(ab, id = min(ab); and the average positive, 
negative test statistics (c8 = ∑ ¯°±(²³,7hhb1 , i8 = ∑ ¯(²³,7hhb1 ). Since the two test 
statistics in each set are symmetric, for simplicity, we will focus on using cd and c8 in 
this chapter.  
First, we introduce some general terms. Let Δ4 be the true mean difference for cell 5, 5 = 1,2, … , 2, and ΔF4 be the estimated differences in sample means. For 2 cells (2 
relatively large), assume there are ]∗ control and l]∗ treatment units in each cell. Assume 
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constant G$ within each cell for both treatment and control. For Z randomly selected 
cells ¤ = (¤, ¤$, … , ¤¨  based on the selection probability _ = Z/2, the Z statistics 
for testing the equality of the means can be written as 
a¤  = x ]∗µ1 + 1l¶ ZG$ g ΔF·¸
¨
¹1 ≜ Q g ΔF·¸
¨
¹1  
In general, to calculate the power, first we calculate a critical value to control for the type 
one error, and then use it to calculate the power. 
» Pr-½(cd(3 > ,7 = RPr-¾(cd(3 > ,7 = 1 −   , 
and 
» Pr-½(c8(3 > ,7 = RPr-¾(c8(3 > ,7 = 1 −  
All the power results will be in terms of _ and `, we will determine the best pair of _ and 
` to use. 
 
3.2.1 Power Calculation with cd 
First, for a given type I error R, a critical value ,7 can be determined by Pr-½(cd(3 > ,7 = R. This equation can be solved using the joint distribution of a(¤ (, a(¤ ($, … , a(¤ (h. Under the null, 
Pr-½(cd(3 < ,7 = 1 − R 
= Pr-½a(¤ ( ≤ ,7 a(¤ ($ ≤ ,7 , … , a(¤ (h ≤ ,7. 
Using the critical value ,7, the power of the test can be represented by 
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Pr-¾(cd(3 > ,7 = 1 −  
under the alternative hypothesis, which can be derived into 
 = Pr-¾a(¤ ( ≤ ,7 a(¤ ($ ≤ ,7 , … , a(¤ (h ≤ ,7. 
The joint distribution of a(¤ (, a(¤ ($, … , a(¤ (h can be represented by `, _, ]∗ 
and l. So we can determine ` and _ by minimizing the type II error , and also this can 
help us design a study by choosing the most appropriate sample size in each treatment 
arm and cell. 
Now we just need to determine the joint distribution of 
a(¤ (, a(¤ ($, … , a(¤ (h. Under the null hypothesis that there is no mean 
difference between the treatment and control in each cell, so a¤ |¤  is (0,1. For 
independently drawn ¤ (, ¤ ($, … , ¤ (h, the joint distribution of a(¤ (, a(¤ ($, …, 
a(¤ (h can be described as  
a(¤ (, … , a(¤ (hM~ À0Xh×, Â1 __ 1 … _… _⋮ ⋮_ _ ⋱ ⋮… 1Åh×hÆ 
according to appendix A. 
The joint distribution of a(¤ (, a(¤ ($, … , a(¤ (h under the alternative hypothesis 
is discussed in two situations, with fixed H4 and random H4. 
3.2.1.1 a(¤ (, … , a(¤ (hMDistribution With Fixed Δ4 
Assume under the alternative hypothesis, each Δ4 has (Ç, È$, and they are fixed. 
This assumption is realistic since the true treatment effect for each subgroup of patients is 
normally fixed.  
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Then a¤ |¤ ~ µQ ∑ ∆·¸¹¨1 , 1¶, and ∑ ∆·¸¹¨1  is approximately normal with 
mean ZÇ and /ZÈ$, where / = (2 − Z/(2 − 1 is the finite sample correction factor, 
followed by a¤ ~(QZÇ, 1 + Q$/ZÈ$. 
According to appendix A, for any a¤(Ê, and a(¤(, y ≠ { and y, { = 1, …, 
`. 
SkËa¤ (Ê, a(¤ ( = na¤ (Êa(¤ ( − n$Ìa¤ Í = _ 
and  
a(¤ (, … , a(¤ (hM 
~ ÎÏÏ
ÐQZÇXh×, Â1 + Q
$/ZÈ$ __ 1 + Q$/ZÈ$ … _… _⋮                    ⋮_                   _ ⋱ ⋮… 1 + Q$/ZÈ$Åh×hÑÒ
ÒÓ 
3.2.1.2 a(¤ (, … , a(¤ (hMDistribution With Random Δ4 
In the situation that Δ4s are random variables, there is no need for the finite 
sample corrector /. After the derivation in appendix A,  
SkËa¤ (Ê, a(¤ ( = na¤ (Êa(¤ ( − n$Ìa¤ Í
= Q$Z$Ç$ + _ + Q$_$2È$ − Q$Z$Ç$ = _ + Q$_$2È$ ≜ _∗ 
a(¤ (, … , a(¤ (hM 
~ ÎÏÏ
ÐQZÇXh×, Â1 + Q
$ZÈ$ _∗_∗ 1 + Q$ZÈ$ … _∗… _∗⋮                    ⋮_∗                   _∗ ⋱ ⋮… 1 + Q$ZÈ$Åh×hÑÒ
ÒÓ 
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3.2.2 Power Calculation with c8 
The idea of calculating the distribution of c8 is to use the central limit theorem. 
Let (b = ZQ,a¤ (b, 0, \ = 1, … , `, then (|∆ÔÕ, …, (h|∆ÔÕ are independent, and 
(b|∆ÔÕ has a normal distribution (b|∆ÔÕ~ µn Ö|∆ÔÕ× , ØQl Ö|∆ÔÕ×¶. By central limit 
theorem, ̅|∆ÔÕ= c8|∆ÔÕ~ µn Ö|∆ÔÕ× , ØQl Ö|∆ÔÕ× `⁄ ¶. The distribution of ̅ = c8 is hard to 
determine, but we can use numerical methods to achieve our goal. To control for the type 
I error to be 0.05, we can calculate a threshold ,7 under the null hypothesis, so that for a 
large number of given ∆ÔÕ b’s, the average probability of µ̅|∆ÔÕ¶bexceeding ,7 is 0.05: 
14¥¦¢ g Ûl Öµ̅|∆ÔÕ¶bb > ,7×
ÜÝÞßà
bb1 = 0.05. 
Since we can calculate the distribution of each µ̅|∆ÔÕ¶bb given µ∆ÔÕ¶bb, the Ûl Öµ̅|∆ÔÕ¶bb >
,7×is easy to write out. 
Before determine n Ö|∆ÔÕ× and ØQl Ö|∆ÔÕ×, we need to know the distribution of 
Q ∑ ∆Õ·¸¹¨1 . Let /7 = (2 − Z (2 − 1á , Q ∑ ∆Õ·¸¹¨1  has an approximately normal 
distribution (QZÇ̂, /7Q$ZÈ̂$, where Ç̂ = ∑ ∆ÕÜâÜãäO   and È̂$ = ∑ ∆ÕÜLåæçâÜãä O . Distribution of Ç̂ 
and È̂$can be calculated based on the distribution of ∆Õ 4. Under the null hypothesis, ∆Õ 4 has 
a normal distribution (0, è7$, where è7$ = éç£∗ (1 + 1/l. Then, Ç̂Q__lk,         ê (0, è7$/2, 
OLë½ç È̂$Q__lk,         ê ì$(2 − 1, and they are independent. 
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With the distribution of Ç̂ and È̂$known, generating a pair of Ç̂ and È̂$ is 
equivalent to generating Δ (where Δ = Δ, … , HO), and then use the estimated ∆ÔÕ  to 
calculate them. For each generated pair of Ç̂ and È̂$, assuming  = QZÇ̂, and S =
í(/7Q$ZÈ̂$ç , then using truncated normal distribution property: 
n Ö|∆ÔÕ× =  n Ömaxa¤ , 0 |∆ÔÕ× = Ûl µa > 0|∆ÔÕ¶ n Öa|∆ÔÕ, a > 0× 
= q1 − Φ ï0 − S ðs q + Sñ ï− Sðs 
where ñ(, = ò(,/ó1 − ô(,õ, ò(, and ô(, are the density function and the  
cumulative probability function of standard normal. 
Ø Ö|∆ÔÕ× =  n Ömax$ a¤ , 0 |∆ÔÕ× − n$ Ömaxa¤ , 0 |∆ÔÕ×
= Pr µa > 0|∆ÔÕ¶  n Öa$¤ |∆ÔÕ, a > 0× − n$ Ömaxa¤ , 0 |∆ÔÕ×
= Pr µa > 0|∆ÔÕ¶ ön Öa$¤ |∆ÔÕ, a > 0× − n$ Öa¤ |∆ÔÕ, a > 0×÷
+ Pr µa > 0|∆ÔÕ¶ n$ Öa¤ |∆ÔÕ, a > 0× − n$ Ömaxa¤ , 0 |∆ÔÕ×
= Pr µa > 0|∆ÔÕ¶  Ø Öa¤ |∆ÔÕ, a > 0× + Pr µa > 0|∆ÔÕ¶ n$ Öa¤ |∆ÔÕ, a > 0×
− n$ Ömaxa¤ , 0 |∆ÔÕ× 
Let è(, = ñ(, ∗ óñ(, − ,õ, then 
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Ø Ö|∆ÔÕ× = q1 − Φ ï0 − S ðs S$ q1 − è ï− Sðs 
+ q1 − Φ ï0 − S ðs q + Sñ ï− Sðs$ + n$ Ö|∆ÔÕ× 
Under the alternative distribution, power can be calculated using 
ÜÝÞßà ∑ Ûl Öµ̅|∆ÔÕ¶bb > ,7×ÜÝÞßàbb1 . The distribution of each µ̅|∆ÔÕ¶bb under the alternative 
distribution can be calculated in two scenarios: with fixed H4 and random H4. 
3.2.2.1 |∆ÔÕ Distribution With Fixed Δ4 
Assume under the alternative hypothesis, each Δ4 has (Ç, È$, and they are fixed. 
The distribution of ∆Õ 4 is then (Ç, è$, where è$ = éç£∗ (1 + 1/l, and Ç̂Q__lk,         ê (Ç, è$/
2,  OLëäç È̂$Q__lk,         ê ì$(2 − 1, and they are independent. 
Similar to n Ö|∆ÔÕ× and Ø Ö|∆ÔÕ× calculated earlier under the null hypothesis. For 
each generated pair of Ç̂ and È̂$ under the alternative hypothesis and the fixed Δ4 
assumption, 
n Ö|∆ÔÕ× =  q1 − Φ ï0 − S ðs q + Sñ ï− Sðs 
and  
Ø Ö|∆ÔÕ× =  q1 − Φ ï0 − S ðs S$ q1 − è ï− Sðs 
                                   + q1 − Φ ï0 − S ðs q + Sñ ï− Sðs$ + n$ Ö|∆ÔÕ× 
where  = QZÇ̂, and S = í(/7Q$ZÈ̂$ç , ñ(, = ò(,/ó1 − ô(,õ, ò(, and ô(, are 
the density function and the cumulative probability function of standard normal. 
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3.2.2.2 |∆ÔÕ Distribution With Random Δ4 
Assume under the alternative hypothesis, each Δ4 has (Ç, È$, and they are 
random. n Ö|∆ÔÕ× and Ø Ö|∆ÔÕ× can be calculated using the exact same formula as above, 
once pairs of Ç̂ and È̂$are generated under the alternative hypothesis with random Δ4 
assunptions. The distribution of ∆Õ 4 in this case is (Ç, è$$, where è$$ = éç£∗ (1 + 1/l +
È$. Ç̂Q__lk,         ê (Ç, è$$/2, OLëçç È̂$Q__lk,         ê ì$(2 − 1, and they are independent. 
 
3.2.3 Unequal ]∗ in Each Cell (Two Values) 
In a population of patients, each cell has equal amount of patients is really rare, 
the more likely situation is most of the cells have a few patients, the rest have more 
patients. Assume ]∗ = ö] _]$ _$, for ` randomly selected cells, ¤ = (¤, ¤$, … , ¤h, 
a(¤ = ∑ øù¸∆Õù¸ú¸ãäø¥µ∑ øù¸∆Õù¸ú¸ãä ¶ where Øû¸ = £ù¸∗∑ £ù¸∗ú¸ãä , then ØQl µ∑ Øû¸∆Õû¸h¹1 ¶ = éçµJäÞ¶∑ £ù¸∗ú¸ãä     
So a(¤ = ∑
üù¸∗∑ üù¸∗ú¸ãä ∆Õù¸ú¸ãä
ý þçµääÞ¶∑ üù¸∗ú¸ãä
= ∑ £ù¸∗ ∆Õù¸ú¸ãä∑ £ù¸∗ú¸ãä éçµJäÞ¶.   
Let   = 1 G$ µ1 + ¶ , under the sharp null that the means are the same between 
the treatment arms and the control arms for all cells, a(¤|¤~(0,1, therefore 
a(¤~(0,1.  
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Given ∆Õ , na(¤|∆Õ =  n ∑ £ù¸∗ ∆Õù¸ú¸ãä∑ £ù¸∗ú¸ãä |∆Õ =   ∑ Øb∆Õ bOb1 nó∑ ]û¸∗h¹1 õ. Let / =
nó∑ ]û¸∗h¹1 õ= ∑ íQ] + (` − Q]$ ïQ`ð _¥ä _$(hL¥äh¥ä17 , then 
SkËÌa¤(, a¤($Í = nÌn$óa(¤õ|∆ÕÍ =  $/$n Ö∑ Øb∆Õ bOb1 $× = /$ ∑ £³∗â³ãä ≜ ∗ 
For independently drawn ¤ (, ¤ ($, … , ¤ (h, the joint distribution of 
a(¤ (, a(¤ ($, …, a(¤ (h can be described as  
a(¤ (, … , a(¤ (hM~ À0Xh×, Â 1 
∗∗ 1 … ∗… ∗⋮ ⋮∗ ∗ ⋱ ⋮… 1 Åh×hÆ. 
Under the alternative distribution, assume 2 ∆bs are fixed and follow (Ç, È$. Then, 
a(¤|¤~(  ∑ Øû¸∆û¸h¹1 , 1 , and ∆û¸~Q__lk,~(Ç, /7È$, /7 = OLhOL. 
nóa(¤õ = nÌnóa(¤|¤õÍ = n   ∑ £ù¸∗ ∆ù¸ú¸ãä∑ £ù¸∗ú¸ãä  =  Çn  ∑ £ù¸
∗ú¸ãä∑ £ù¸∗ú¸ãä (Assume ∆Õ⊥ ]∗) 
                =  Çn q∑ ]û¸∗h¹1 s =  /Ç, where / = n q∑ ]û¸∗h¹1 s  
ØQlóa(¤õ = nÌØQlóa(¤|¤õÍ + ØQlÌnóa(¤|¤õÍ = 1 +  $ØQl ∑ £ù¸∗ ∆ù¸ú¸ãä∑ £ù¸∗ú¸ãä  ≜ è$. 
ØQl ∑ £ù¸∗ ∆ù¸ú¸ãä∑ £ù¸∗ú¸ãä  = /7È$n ∑ £ù¸
∗ çú¸ãä∑ £ù¸∗ú¸ãä 	 + Ç$(`(_] + _$]$ − /$ = 1 +  $ó/7È$
 +
Ç$(`(_] + _$]$ − /$õ, where 
 = n ∑ £ù¸∗ çú¸ãä∑ £ù¸∗ú¸ãä 	 =
∑ pÌ¥ä£äçJ(hL¥ä£ççÍ¥ä£äJ(hL¥ä£ç ïQ`ð _¥ä _$(hL¥äth¥ä17 .  
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nÌa¤(a¤($Í = nÌn$óa(¤õ|∆ÕÍ =  $/$n Ö∑ Øb∆Õ bOb1 $× = ç∑ £³∗â³ãä +  $/$Ç$   
⇒  SkËÌa¤(, a¤($Í = nÌa¤(a¤($Í − nÌa¤(ÍnÌa¤($Í  
                                              = ç∑ £³∗â³ãä +  $/$Ç$ −  $/$Ç$ ≜ $∗ 
a(¤ (, … , a(¤ (hM~ ÎÏÏ
Ð /ÇXh×, 
è$ $∗$∗ è$ … $∗… $∗⋮   ⋮$∗ $∗ ⋱ ⋮… è$

h×hÑÒ
ÒÓ 
More detailed derivation can be found in appendix B.  
 
3.2.4 Unequal ]∗ in Each Cell (Shifted Poisson Distribution) 
Sometimes, ]∗ may follow a certain distribution, in this dissertation, shifted 
Poisson distribution was used as an example. Numerical methods were also applied to 
help calculate certain values. Detailed derivation can be found in appendix C. 
Assume ,~_k\yyk](ñ, and let ]∗ = , + 1, then ]∗ is shifted Poisson distributed. 
For ` randomly selected cells, ¤ = (¤, ¤$, … , ¤h, a(¤ = ∑ øù¸∆Õù¸ú¸ãäø¥µ∑ øù¸∆Õù¸ú¸ãä ¶ where 
Øû¸ = £ù¸∗∑ £ù¸∗ú¸ãä . Since ØQl µ∑ Øû¸∆Õû¸h¹1 ¶  = éçµJäÞ¶∑ £ù¸∗ú¸ãä , then a(¤ = ∑ £ù¸∗ ∆Õù¸ú¸ãä∑ £ù¸∗ú¸ãä éçµJäÞ¶.   
Let   = 1 G$ µ1 + ¶ , under the sharp null that the means are the same between the 
treatment arms and the control arms for all cells, a(¤|¤~(0,1, therefore 
a(¤~(0,1. Similarly, given ∆Õ , na(¤|∆Õ =  n ∑ £ù¸∗ ∆Õù¸ú¸ãä∑ £ù¸∗ú¸ãä |∆Õ =
  ∑ Øb∆Õ bOb1 nó∑ ]û¸∗h¹1 õ. Since ,û¸~Ûk\yyk](ñ, then v ≜ ∑ ,û¸h¹1 ~Ûk\yyk](`ñ. 
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Let / ≜ n q∑ ]û¸∗h¹1 s = nÌív + `Í = ∑ ív + ` ! L17 , which can be calculated by 
Monte Carlo Method. So SkËÌa¤(, a¤($Í = nÌn$óa(¤õ|∆ÕÍ = /$ ∑ £³∗â³ãä ≜ ∗. 
Above all, under Null, Ìa¤(, a¤($ÍM~ qµ00¶ , ï 1 ∗∗ 1 ðs. 
For independently drawn ¤ (, ¤ ($, … , ¤ (h, the joint distribution of 
a(¤ (, a(¤ ($, …, a(¤ (h can be described as  
a(¤ (, … , a(¤ (hM~ ÎÏÏ
Ð0Xh×, Â 1 
∗∗ 1 … ∗… ∗⋮ ⋮∗ ∗ ⋱ ⋮… 1 Åh×hÑÒ
ÒÓ 
Under alternative hypothesis, a(¤|¤~(  ∑ Øû¸∆û¸h¹1 , 1 , and 
∆û¸~Q__lk,~(Ç, /7È$, /7 = OLhOL. 
nóa(¤õ = nÌnóa(¤|¤õÍ =  Çn  ∑ £ù¸∗ú¸ãä∑ £ù¸∗ú¸ãä   (assume ∆Õ⊥ ]∗) 
                =  Çn q∑ ]û¸∗h¹1 s =  /Ç  where / = n q∑ ]û¸∗h¹1 s, and 
ØQlóa(¤õ = nÌØQlóa(¤|¤õÍ + ØQlÌnóa(¤|¤õÍ = 1 +  $ó/7È$
 + Ç$(`ñ + ` −
/$õ, where 
 = n ∑ £ù¸∗ çú¸ãä∑ £ù¸∗ú¸ãä 	, which can be calculated by Monte Carlo 
nÌa¤(a¤($Í = nÌn$óa(¤õ|∆ÕÍ =  $/$n Ö∑ Øb∆Õ bOb1 $× = ç∑ £³∗â³ãä +  $/$Ç$  
⇒  SkËÌa¤(, a¤($Í = nÌa¤(a¤($Í − nÌa¤(ÍnÌa¤($Í =
ç∑ £³∗â³ãä +  $/$Ç$ −  $/$Ç$ ≜ ∗ 
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a(¤ (, … , a(¤ (hM~ ÎÏÏ
Ð /ÇXh×, 
è$ ∗∗ è$ … ∗… ∗⋮   ⋮∗ ∗ ⋱ ⋮… è$

h×hÑÒ
ÒÓ 
 
3.3 Simulation 
There are two objectives of the simulation. One is to discover how the power 
changes when each parameter changes in the test. The other is to compare the results 
between the power calculated by theory and by simulation. For each objective, the 
simulation section will consist two parts, the power simulation using cd, and using c8. 
The following parameter combinations were used:  
1. For equal number of patients in each cell ]∗ = 3,5,10,15, or 
2. ]∗ = p 5 _ = 0.820 _$ = 0.2, or ]∗ = p 5 _ = 0.830 _$ = 0.2, or 
3. ]∗ = , + 1, ,~_k\yyk](5, ,~_k\yyk](10 
4. 2 = 30,100 
5. G$ = 1.5, 2, 2.5, 3 
6. È$ = 0.25, 0.5, 1, 1.5 
7. l = 1, 2 
For both section in the second objective, under the null hypothesis, the outcomes 
for patients under treatment and control for all 2 cells were generated from the same 
normal distribution (1, G$. Under the alternative hypothesis, the outcomes under the 
control were generated from (0, G$. If using fixed ∆Ô , one set of ∆Ô  was generated from 
(Ç, È$, and was used to generate the outcomes under the treatment by each cell. For 
cell 5, the outcomes were generated using (Δ4, G$, 5 = 1,2, … , 2. 
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3.3.1 Objective One 
Powers were calculated in different settings, to better show how each parameter 
affects the power, selected results will be shown in figures. In each setting, the pair of 
(`, Z corresponding to the best power was used. 
3.3.1.1 Power Simulation Using cd 
Figure 1 Power Plot of 2 = 100, l = 1, and Equal Cell Size ]∗ = 3,5,10,15, 
G$ = 2, 3, È$ = 0.25, 0.5, 1, 1.5 using cd 
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3.3.1.2 Power Simulation Using c8 
Figure 2 Power Plot of 2 = 100, l = 1, and Equal Cell Size ]∗ = 3,5,10,15, 
G$ = 2, 3, È$ = 0.25, 0.5, 1, 1.5 
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3.3.2 Objective Two 
3.3.2.1 Power Simulation Using cd 
The type I errors were checked for different scenarios by simulations using cd. 
The selected results are shown in Table 23. When ` is large enough, the type I error is 
fairly stable around 0.05.  
Table 23 Type I error results for 2 = 100, l = 1, ]∗ = 10, G$ = 1 
 
   
 
30 50 100 200 300 
3 0.046 0.039 0.053 0.053 0.051 
5 0.064 0.05 0.047 0.037 0.057 
10 0.039 0.05 0.043 0.052 0.046 
15 0.045 0.041 0.048 0.041 0.054 
20 0.045 0.048 0.056 0.048 0.053 
30 0.038 0.056 0.036 0.055 0.042 
35 0.035 0.05 0.051 0.049 0.036 
40 0.045 0.052 0.036 0.046 0.048 
50 0.045 0.044 0.059 0.047 0.046 
60 0.06 0.055 0.047 0.037 0.055 
 
The powers calculated by the extreme value method were compared with the 
simulations. The comparisons were shown in Figure 3. We can see, when the power is 
small (power<0.5), the two methods have similar results, however, when the power is 
getting larger, the extreme value method tends to over estimate the power.  
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Figure 3 Results comparison between the extreme value method and the simulation 
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3.3.2.2 Power Simulation Using c8 
The type I errors were checked for different scenarios by simulations using c8. 
The selected results are shown in Table 24. When ` is large enough (` > 300), the type I 
error is fairly stable around 0.05.  
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Table 24 Type I error results for 2 = 100, l = 1, ]∗ = 10, G$ = 1.5 
 
   =    =   =   =   =  
5 0.0295 0.0352 0.0373 0.0406 0.0384 
10 0.0355 0.0366 0.0417 0.0456 0.048 
15 0.0369 0.0435 0.0467 0.0493 0.0484 
20 0.0401 0.0444 0.0446 0.0451 0.048 
25 0.0428 0.0482 0.046 0.0477 0.0467 
30 0.0408 0.0462 0.0493 0.0493 0.049 
35 0.0419 0.0426 0.0484 0.0505 0.047 
40 0.0451 0.0444 0.0479 0.0469 0.0485 
45 0.0446 0.0461 0.049 0.047 0.0486 
50 0.0463 0.0446 0.0467 0.0472 0.0548 
55 0.0449 0.0494 0.0495 0.049 0.0501 
60 0.0487 0.0474 0.0454 0.0515 0.0503 
   =   =   =   =   =  
5 0.0453 0.0463 0.0455 0.0471 0.0471 
10 0.0503 0.0457 0.0504 0.0453 0.0463 
15 0.0453 0.0485 0.0489 0.0468 0.0486 
20 0.0456 0.0491 0.0461 0.045 0.0486 
25 0.0479 0.0486 0.0498 0.0452 0.0521 
30 0.0489 0.045 0.0502 0.0487 0.0503 
35 0.0504 0.0493 0.0523 0.0501 0.0467 
40 0.0505 0.0505 0.0454 0.0479 0.0508 
45 0.0492 0.0483 0.049 0.0486 0.0513 
50 0.0516 0.0464 0.053 0.0512 0.0489 
55 0.0478 0.0488 0.0481 0.049 0.0488 
60 0.0513 0.0488 0.0475 0.0492 0.0498 
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The powers calculated by the average value method were compared with the 
simulations. The comparisons were shown in Figure 4. The figure shows the two methods 
have similar results.  
 
Figure 4 Results comparison between the average value method and the simulation 
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3.4 Discussion 
In this chapter, some theoretical methods were proposed to help determine the 
most appropriate study design, such as how many subjects in each cell to achieve certain 
desired power. 
Normal approximation was used in the extreme value method, and hence induced 
some bias when reach high power. The central limit theorem was used in the average 
value method, and no obvious bias detected comparing to the simulation results.  
For both methods, the larger the constant G$ within each cell (for both treatment 
and control), the lower the power of the tests; while the greater the sample size ]∗in each 
cell, and the greater the variance (È$) among the true mean difference (Δ4) for different 
cells, the higher the power of the tests. In other words, smaller G$, larger ]∗ and È$ make 
the tests easier to reject the null hypothesis that there is no treatment difference. 
All the simulation results shown in this chapter were under the assumption that 
each cell has equal sample size, however, in the real circumstances, there could be two or 
more different sample sizes in different cells, sometimes the sample sizes may follow a 
specific distribution. The study design can be extended to accommodate these situations, 
which were mentioned in the method section.  
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CHAPTER 4. LOGISTIC-COX PROPORTIONAL HAZARDS MIXTURE MODEL 
4.1 Background 
Mixture models have been applied to different settings in survival analysis. 
Farewell[25, 26] used the combination of logistic regression with proportional hazards 
regression to distinguish the individuals who will eventually experience the event and the 
ones who will never experience the event in the model. Kuk et al.[27] proposed a 
semiparametric mixture model based on Farewell’s parametric model.  Ng and 
McLachlan[28] developed a semiparametic mixture model approach to analyze the 
competing-risks data. Peng and Dear[29] studied a general nonparametric mixture model 
to estimate the cure rate of the patients. In addition, Corbière et al. [30]proposed a 
penalized likelihood approach in the mixture cure model to allow flexible hazard function 
assumption and direct way to calculate the variance of parameters.  
In this chapter, the mixture model was used to model the heterogeneity of the 
treatment effect. The treatment effect on any given patient can be conceptually defined, 
but estimation is impossible in most studies as we only observe one outcome (either 
under control or intervention). Let  = 1 represents the patient under the treatment,  be 
the corresponding outcome, and  = 0 represents the patient under the control, 7 be the 
corresponding outcome. Then the outcome  can be described as  =  + (1 − 7. 
One can only observe either  or 7, not both, so the treatment effect Δ =  − 7 can 
not be directly calculated for each patient. Although we reply on average treatment effect, 
we can assume different groups to have different average treatment effect. In our 
proposed mixture model, we define there are two groups, one with the benefit averaged 
treatment effect, and the other one without. The probability of a patient in either group 
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can be calculated with the given information about each patient, and used as a weight in 
the proposed model. Different survival models can be constructed for the two groups 
separately to analyze the characteristic and treatment effect of each group.  
In section 2, we introduce the mixture model, EM algorithm and other techniques 
used in the simulations, which are demonstrated in section 3. In section 4, the mixture 
model is applied to the MADITII data again, followed by discussion in section 5. 
 
4.2 The mixture model  
4.2.1 Cox proportional hazard (CoxPH) model  
Given data ({b, èb, ,b, \ = 1, … , ], where {b is the event time when èb = 1, and {b 
is the censored time when èb = 0, ,b is the covariate vector. In the CoxPH model, for the \th individual, it is assumed that 
ñ({; ,b = ñ7({exp (,bM Ô +  8 
where ñ({; ,b is the hazard for individual \ at time {, given covariate values ,b, and ñ7({ 
is the baseline hazard function of {.  8 is the coefficient of the treatment, when  8 < 0, 
the treatment reduces the hazard, and vice versa. If we order the event time as 3∗ distinct 
time: { < {$ < ⋯ < {∗ with no tied events, then  Ô can be estimated by maximizing the 
partial likelihood   
 exp ó,(¹M  Ô +  8õ∑ exp ó,hM Ô +  8õh∈¸
∗
¹1  
where {¹ represents all individuals at risk at a time just prior to {¹, and ,(¹ is the 
covariate vector of the individual whose failure time is {¹. 
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4.2.2 Mixture Model and EM Algorithm 
To set up the mixture model, we introduce a latent variable a, the benefit 
indicator, i.e. a = 1 indicates the individual is in the group that assumed to have benefit 
average treatment effect ( 8 < 0), and a = 0 means the individual is in the other group 
( 8 ≥ 0). For simplicity, we call the individuals who have a = 1 in the ‘benefit group’, 
and the rest who have a = 0 in the ‘not benefit group’. a is assumed to have a Bernoulli 
distribution with probability _, which is modeled as a logistic model: 
log ï _1 − _ð = 6MÔ 
where 6 are covariates, such as baseline characteristic variables. 6 can be the same or 
different as }Ô. 
Our mixture model consists of two parts, the logistic regression part, and the 
survival part. The logistic regression part describes the probability of an individual in the 
‘benefit group’, and the survival part is the corresponding survival probability. Let b be 
the survival likelihood function if individual \ is in the ‘benefit group’, and ℎb be the 
function if he/she is in the ‘not benefit group’. If we have the complete set of data 
(}, i, a, the likelihood for individual \ can be represent as  
2b = /(,b_b³(1 − _bL³b³ℎb(L³  
b and ℎb are assumed in the form of Ìñ7({ exp,M Ô +  8Íëc7(i± !"¡ÔJ8¡¾ with 
the proportional hazard assumption. The only difference between the two functions is the 
assumption about the coefficients for treatment.  
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Since a cannot be directly observed, the dataset (}, i, a is not complete; EM 
algorithm can be used to solve the problem. The observed likelihood for individual \ can 
be written as 
2b# = /(,b(Pr(a = 1 b + Pr(a = 0 ℎb.  
Let $Ô represents the unknown parameters in the model. To start the process of estimating 
$Ô, assume initial values $Ô(7. The process will be illustrated at the `th iteration, ` =
0,1, …%. $Ô(h is used to denote the current value of $Ô, and 5]2b#(h can be estimated by 
plugging in $Ô(h. E step is performed to calculate: 
n&(úÌ5]2($'$Ô(h, }, iÍ = g ­b5]_b + (1 − ­b5](1 − _b + ­b5]b + (1 − ­b5]ℎb£b1  
where ­b = Pr óab = 1|$Ô(h, }, iõ. Then $Ô(hJ is estimated and updated in the M step by 
solving the weighted logistic model and the weighted CoxPH model. At the end of the M 
step, calculate 5]2b#(hJ. The EM algorithm improves the observed log-likelihood, i.e. 
5]2b#(hJ −  5]2b#(h is always positive. Repeat the E step and the M step, until the %th 
iteration where 5]2b#((J −  5]2b#(( is sufficiently small. 
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4.2.3 Baseline Hazard ñ7({ Estimation 
After    F  and  8o were estimated using partial likelihood, they can be plug into the 
likelihood function, and the likelihood function can be written in a function of the 
baseline hazard ñ7({: 
Lβ (λ0 (t))∝ λ0 (ti )exp −λ0 (ti ) e j
j∈R(ti )
∑















i=1
D*∏  
where . 
LLβ λ0 (t)( ) = log λ0 (ti )( ) − λ0 (ti ) e j
j∈R(ti )
∑







i=1
D
∑ ⇒ ∂∂λ0 (ti )
=
1
λ0 (ti )
− e j
j∈R(ti )
∑ = 0  
⇒ λˆ0 (t) =
1
e j
j∈R(ti )
∑
= z j exp(β beAj )+ (1− z j )exp(β nbAj )
j∈R(ti )
∑






−1
 
The more detailed derivation can be found in the appendix. 
 
4.2.4 Louis’s Method 
Louis’s method is used to calculate the standard errors of the estimators estimated 
by the EM algorithm. At the last (%th) iteration of the M step,  $ ois estimated to 
maximize n&(úÌ5]2($'$Ô((, }, iÍ. Define cB($;}, i, a to be the score function of 
∑ 5]2b£b1 , then the information matrix X µ $ o;}, i¶ can be calculated by: 
X µ $ o;}, i¶ = XB µ $ o;}, i¶ − X¨ µ $ o;}, i¶ 
where XB$Ô((;}, i = n& ö− )ç)&)&" 5]2B($|}, i÷&1 & o  and X¨ $Ô((;}, i =óSkË&NcB($;}, i, a|}, iPõ&1 & o .  
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4.2.5 Calculate Treatment Benefit and Treatment Harm Rate 
Treatment benefit rate (TBR) and treatment harm rate (THR) can be used to 
describe the proportion of the patients that benefit or harmed by the treatment as 
compared with the control respectively[31]. They are also important measurements to 
describe the heterogeneity within the given group of patients, although they describe 
things slightly different than a. In the setting of survival outcomes, a = 1 indicates that 
an individual survives longer under the treatment than under the control, regardless the 
actual survival time.  Whereas in the calculation of TBR, ‘benefit’ means an individual 
survives beyond a fixed time threshold under treatment and dies before the threshold 
under control. 
According to the paper[31], in the time-to-event outcome case, assume 
c7({ = Pr(i > {|},  = 0, 
c({ = Pr(i > {|},  = 1, 
then TBR and THR can be expressed as 
i({ = nó1 − c7({c({õ, 
i6({ = nÌc7({1 − c({Í. 
In our situation with the un-observed parameter a, the expressions become 
i({ = nóa µ1 − c¡¢£¢§b7 ({¶ c¡¢£¢§b ({ + 
(1 − a µ1 − c*M¡¢£¢§b7 ({¶ c*M¡¢£¢§b ({õ, 
i6({ = nóac¡¢£¢§b7 ({ µ1 − c¡¢£¢§b ({¶ + 
(1 − ac*M¡¢£¢§b7 ({ µ1 − c*M¡¢£¢§b ({¶õ. 
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4.3 Simulation 
4.3.1 Objective 
There are two objectives for the simulation. The first one is to examine the 
performance of the mixture model with simulated patient data. The second one is to 
compare the Louis’s method estimated standard error with the true standard error. 
4.3.2 Data and Setting 
Data were simulated based on the MADIT II data, the same dataset as in 
Chapter2.  
For objective one, ] =1,000 and 10,000 patients were simulated with patients’ 
age, sex, health index, treatment assignment. Each patient’s age was generated from a 
normal distribution with mean 50 and standard deviation of 2. Probability of a male 
patient is 0.5, and the probability of being assigned to treatment arm is also 0.5. Health 
indexes were generated from the standard normal distribution. The probability of a 
patient benefiting from the treatment is determined by health index (6) – the logistic 
regression part. The logit of the probability for each patient to benefit is a linear function 
of his/her health index: 
_b+¢ = exp(6 /(1 + exp (6 
The benefit indicator (ab) for each patient was then generated using _b+¢.  
Two different sets of coefficients were assumed for the ‘benefit group’ and the 
‘not benefit group’. Particularly,  8 was assumed to be a negative number for the ‘benefit 
group’ and a non-negative number for the ‘not benefit group’. The time to event was then 
generated with the rate based on a patient’s age, sex, and treatment assignment for each 
group respectively using exponential distribution: 
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lQ{ = a × Ìñ7({ exp,M Ô¡¢ +  8¡¢Í + (1 − a × Ìñ7({ exp,M Ô£¡ +  8£¡Í. 
For objective two, ] =1000 patients were simulated in a simple setting with only 
health index (6) and treatment assignment (). The coefficients for treatment assignment 
 8 in the ‘benefit group’ and ‘not benefit group’ were assumed to be negative and non-
negative respectively. Monte Carlo simulations for 200, 500, 1000, and 5000 times were 
completed to calculate both the bootstraping and Louis’s method estimation of standard 
error of each parameter. The difference between the two sets of standard errors was then 
compared. 
 
4.3.3 Selected Results for Objective One 
Different coefficients were used to discover the characteristic of the mixture 
model. In this dissertation, two scenarios are presented. Both scenarios have the same 
beneficial treatment effect in the ‘benefit group’. While first scenario has harmful 
treatment effect in the ‘not benefit group’, the second scenario has no treatment effect in 
that group. In addition, the second scenario added a intercept parameter into the model, 
The true value, the estimated value, and the standard error of each coefficient, are shown 
in the tables below for ] =1,000 and ] =10,000. 
  
  61
 
Table 25 First Scenario ] =1,000 
n=1,000 Health 
Index 
() 
BG-
age 
() 
BG-
sex 
() 
BG-
trt 
(¬) 
NBG-
age 
() 
NBG-
sex 
() 
NBG-
trt 
(¬) 
Mixture 
Model Results 
1.232 1.038 -0.649 -0.991 0.275 -0.330 0.537 
True Value 1 1 -0.8 -1 0.3 -0.3 0.5 
Standard 
Error 
0.182 0.081 0.213 0.211 0.033 0.141 0.142 
 
Table 26 First Scenario ] =10,000 
n=10,000 Health 
Index 
() 
BG-
age 
() 
BG-
sex 
() 
BG-
trt 
(¬) 
NBG-
age 
() 
NBG-
sex 
() 
NBG-
trt 
(¬) 
Mixture 
Model 
Results 
0.904 0.984 -0.808 -0.943 0.291 -0.309 0.468 
True Value 1 1 -0.8 -1 0.3 -0.3 0.5 
Standard 
Error 
0.078 0.027 0.068 0.073 0.011 0.045 0.052 
 
The comparison of the computed and the true baseline cumulative hazard over 
time are shown in the figures. 
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Figure 5 Baseline Cumulative Hazard over Time ] =1,000 
 
Figure 6 Baseline Cumulative Hazard over Time ] =10,000 
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Table 27 Second Scenario ] =1,000 
n=1,000 Intercept Health 
Index 
BG-
age 
BG-
sex 
BG-
trt 
NBG-
age 
NBG-
sex 
NBG
-trt 
Mixture 
Model 
Results 
-0.231 1.315 0.895 -0.831 -0.716 0.247 -0.268 
4.941
E-06 
True 
Value 
-0.5 1 1 -0.8 -1 0.3 -0.3 0 
Standar
d Error 
0.476 0.329 0.167 0.285 0.198 0.045 0.128 0.077 
 
Table 28 Second Scenario ] =10,000 
n=10,000 Intercept Health 
Index 
BG-
age 
BG-
sex 
BG-
trt 
NBG
-age 
NBG-
sex 
NBG
-trt 
Mixture 
Model 
Results 
-0.559 0.955 0.986 -0.730 -0.991 0.300 -0.334 
1.204
E-07 
True 
Value 
-0.5 1 1 -0.8 -1 0.3 -0.3 0 
Standard 
Error 
0.116 0.082 0.037 0.074 0.082 0.013 0.038 0.024 
 
Table 29 Results for Objective Two ] =1,000,  =200 
n=1,000 B=200 seed=123 
 
 
 ¬ ¬ 
True SE 0.131 0.198 0.159 
Louis's Method 
SE 
0.121 0.212 0.145 
Difference 0.010 -0.013 0.014 
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Table 30 Results for Objective Two ] =1,000,  =500 
n=1,000 B=500 seed=736 
 
 
 ¬ ¬ 
True SE 0.116 0.212 0.155 
Louis's Method 
SE 
0.121 0.211 0.145 
Difference -0.005 0.001 0.010 
 
Table 31 Results for Objective Two ] =1,000,  =1,000 
n=1,000 B=1000 seed=3294   
   ¬ ¬ 
True SE 0.118 0.211 0.151 
Louis's Method 
SE 
0.121 0.212 0.145 
Difference -0.003 -0.001 0.006 
 
Table 32 Results for Objective Two ] =1,000,  =500 
n=1,000 B=5000 seed=123   
   ¬ ¬ 
True SE 0.121 0.213 0.151 
Louis's Method 
SE 
0.121 0.213 0.145 
Difference 0.000 0.001 0.006 
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4.4 Application to MADITII Data 
The mixture model was applied to the MADITII data using, the five clinical 
characteristic variables in the logistic regression part, and the five clinical characteristic 
variables in the survival part. Two year TBR and THR were calculated and compared 
with the results in the paper of Shen et al[31].   
Table 33 Results of TBR , THR, and the Mean Posterior Probability of ab 
TBR  THR the mean of posterior probability of Zi 
0.176 0.098 0.962 
   
From the results in the table, we can see that 17.6% of the patients who can 
survive beyond two years under treatment would die before two years under control 
(compare to 18% in Shen et al.[31]); while 9.8% patients would die within two years in 
the treatment arm but survive in the control arm (compare to 10% in Shen et al.[31]). The 
average probability of an individual survives longer under the treatment than under the 
control, regardless the actual survival time is 0.962. 
 
4.5 Discussion  
n=1000 seems sufficient to estimate the coefficients well. Clearly, when there are 
more patients, the mixture model gives better estimation. 
As mentioned earlier, in the logistic part of the model, baseline characteristic 
variables (6) are used to determine the model of a. In some cases, there are maybe 
hundreds even thousands baseline variables for us to use. To select the important 
variables for the model, some variable selection method, such as the LASSO selection 
procedure, can be added in the M step when solving the weighted logistic regression. 
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In this dissertation, we simply used 0 as the threshold to separate the two groups, 
i.e. the ‘benefit group’ is assumed to have  8 < 0, and the ‘not benefit group’ is assumed 
to have  8 ≥ 0. This means on average in the ‘benefit group’, the treatment reduces the 
hazard, and in the ‘not benefit group’, the treatment is the same as the control or even 
increase the hazard.  
Other threshold values can be chosen depending on the nature of the treatment. 
Sometimes, we may want to choose a negative value instead of 0 as the threshold, for 
example, when both sub groups are beneficial from the treatment, with one group benefit 
more than the other. 
We need to try to confirm the existence of two groups with (quantitatively or 
qualitatively) different treatment effect by either testing or by experience before using the 
mixture model. Since there is a constraint in the model, it forces  8s to separate by the 
threshold. Our simulation shows, if both  8s are actually on the same side, and the 
threshold assumption is wrong, then the estimation of the one  8that assumed to be on the 
wrong side of the threshold, will be really close to the threshold, and the other 
coefficients for all the other parameters will be estimated poorly. 
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CHAPTER 5 CONCLUSIONS AND DISCUSSIONS 
Heterogeneity of the treatment effect in the treated population is frequently 
encountered in medical research. The literature of testing is dominated by either 
improved subgroup analysis with fixed subgroups, or by post hoc subgroup search with 
certain model assumptions. In this dissertation, we proposed a non-parametric test 
adopting G&S’s likelihood ratio test, and P&G’s range test. We extended their tests with 
a built-in stochastic search. This extension allows us to detect signals that may not be 
linearly related to the multiple covariates. The one-sided and two-sided extreme value 
tests are based on the strongest positive and negative signals, while one-sided and two-
sided average value tests are based on the average positive and negative signals. The 
choice for the pair of ` and _ in the stochastic search are essential to this test. We 
evaluated our methods through simulation study and applied this method to the MADIT 
II data. Nevertheless, active search is prone to selection bias and inflation of the 
probability of false positives. Our test can serve as a gatekeeping procedure to prevent 
false positives.   
Using our proposed test, with some knowledge of the targeted patient population, 
we can calculate power under different settings to help guide future study designs. We 
focused on normal distributed outcomes in this chapter. It seems like the ‘extreme value 
test’ works better than the ‘average value test’ when the true treatment effects are from a 
normal distribution. Without surprise, changing from 3 patients in each cell, to 10 
patients in each cell (in each treatment arm) can considerably increase the power of our 
tests. In addition, larger variance between the true treatment effects, and less variation of 
the treatment effect for patients within each cell, improve the power as well. Although 
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formulation maybe hard to derive in other outcomes, such as survival outcomes, one can 
certainly use numerical methods to calculate powers for study design. Faster 
computational methods may need to be developed to be able to handle large calculations.    
Finally, we developed a mixture model to model the patients who benefit from the 
treatment and who do not, and to estimate the average treatment effect in different sub-
populations.  In our proposed mixture model, we defined two groups, with and without 
the benefit averaged treatment effect. We calculated the posterior probability of each 
patient in either group with the given clinical knowledge about each patient, and used it 
as a weight in the proposed model. Different survival models were constructed for the 
two groups separately to analyze the characteristic and treatment effect of each group. 
The mixture model can be easily extend to serve more than two sub-populations, however, 
one should bear in mind that more available patient samples may be required to estimate 
all parameters in a more complex model. We evaluated our methods through simulation 
study and applied this method to the MADIT II data. The use of this method allows us to 
discover the treatment effects when qualitative treatment interactions exist, to separate 
patients into different groups, and to estimate the average treatment effect in different 
sub-populations. 
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APPENDIX A DISTRIBUTION OF a(¤ (, … , a(¤ (hMUNDER NULL AND 
ALTERNATIVE HYPOTHESES 
For Z randomly selected cells, _ = Z/2, ¤ = (¤, … , ¤¨ , the a statistic for testing 
the equality of the means is of the form 
a¤  = x ]∗µ1 + 1l¶ ZG$ g ∆Õû¸
¨
¹1 ≜ Q g ∆Õû¸
¨
¹1 . 
Under the sharp null that the means are the same between the treatment arms for all cells, 
a¤ |¤ ~(0,1, and therefore a¤ ~(0,1. For two independent draws, ¤ ( and 
¤ ($, we have SkËa¤ (, a(¤ ($ = na¤ (, a(¤ ($ = 
n Ön µa¤ (, a¤ ($¶ |H× = nÌna¤ (|Hna¤ ($|HÍ =
nÌn$a¤ ($|HÍ = Q$n Ö_ ∑ HbOb1 $× = ¥ç,çOµJäÞ¶éç£∗ = _. (Note that 
n Ö∑ ∆Õû¸¹¨1 |H× = _ ∑ HbOb1 ). Since for any a¤ (Ê and a(¤ (, y ≠ { and y, { =
1, … , `, SkËa¤ (Ê, a(¤ ( is the same value, the distribution of 
a(¤ (, a(¤ ($, …, a(¤ (h can be described as  
a(¤ (, … , a(¤ (hM~ À0.ú×ä , Â1 __ 1
… _… _⋮ ⋮_ _ ⋱ ⋮… 1ÅÆ. 
Under the alternative hypothesis, Δ4~(Ç, È$, a¤ |¤ ~ µQ ∑ ∆·¸¹¨1 , 1¶, and 
∑ ∆·¸¹¨1  is approximately normal with mean ZÇ and /ZÈ$, where / = (2 − Z/(2 −
1 is the finite sample correction factor. Then, when Δ4s are fixed, a¤ ~(QZÇ, 1 +
Q$/ZÈ$. 
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For any a¤ (Ê, and a(¤ (, y ≠ { and y, { = 1, … , `,  
na¤ (Êa(¤ ( = nÌn$a¤ |∆ÕÍ = Q$_$n /g ∆Õ bOb1 0
$
= Q$_$ 1n$ /g ∆Õ bOb1 0 + Ø /g ∆Õ b
O
b1 02
= Q$_$2$Ç$ + Q$_$ 2 (1 + 1/lG$]∗ 	 = Q$Z$Ç$ + _ 
SkËa¤ (Ê, a(¤ ( = na¤ (Êa(¤ ( − n$Ìa¤ Í
= Q$Z$Ç$ + _ − Q$Z$Ç$ = _ 
Then,a(¤ (, … , a(¤ (hM 
~ ÎÏÏ
ÐQZÇ.ú×ä , Â1 + Q
$/ZÈ$ _ … __ 1 + Q$/ZÈ$ … _⋮ ⋮ ⋱ ⋮_ _ … 1 + Q$/ZÈ$ÅÑÒÒ
Ó
 
Then, when Δ4s are random, a¤ ~(QZÇ, 1 + Q$ZÈ$. For any a¤ (Ê, and 
a(¤ (, y ≠ { and y, { = 1, … , `, 
na¤ (Êa(¤ ( = Q$_$ 1n$ /g ∆Õ bOb1 0 + Ø /g ∆Õ b
O
b1 02
= Q$_$2$Ç$ + Q$_$ 2 (1 + 1/lG$]∗ + 2È$	 = Q$Z$Ç$ + _ + Q$_$2È$ 
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SkË µa¤ (Ê, a¤ (¶ = n µa¤ (Êa¤ (¶ − n$Ìa¤ Í
= Q$Z$Ç$ + _ + Q$_$2È$ − Q$Z$Ç$ = _ + Q$_$2È$ ≜ _∗ 
Then,a(¤ (, … , a(¤ (hM 
~ ÎÏÏ
ÐQZÇ.ú×ä , Â1 + Q
$ZÈ$ _∗ … _∗_∗ 1 + Q$ZÈ$ … _∗⋮ ⋮ ⋱ ⋮_∗ _∗ … 1 + Q$ZÈ$ÅÑÒÒ
Ó. 
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APPENDIX B FORMULATION OF POWER CALCULATION FOR UNEQUAL 
PATIENT SAMPLE SIZE CASE (TWO VALUES) 
Assume ]∗ = ö] _]$ _$,  
For ` randomly selected cells, ¤ = (¤, ¤$, … , ¤h 
  a(¤ = ∑ øù¸∆Õù¸ú¸ãäø¥µ∑ øù¸∆Õù¸ú¸ãä ¶ where Øû¸ = £ù¸∗∑ £ù¸∗ú¸ãä  
ØQl µ∑ Øû¸∆Õû¸h¹1 ¶ = ∑ Øû$¸ ØQl µ∆Õû¸¶ =h¹1 ∑ Øû$¸ éç£ù¸∗ µ1 + ¶h¹1 =
∑ üù¸∗ çþçüù¸∗ µJäÞ¶ú¸ãäµ∑ £ù¸∗ú¸ãä ¶ç  =
éçµJäÞ¶ ∑ £ù¸∗ú¸ãä
µ∑ £ù¸∗ú¸ãä ¶ ç = é
çµJäÞ¶∑ £ù¸∗ú¸ãä     
a(¤ = ∑
üù¸∗∑ üù¸∗ú¸ãä ∆Õù¸ú¸ãä
ý þçµääÞ¶∑ üù¸∗ú¸ãä
= ∑ £ù¸∗ ∆Õù¸ú¸ãä∑ £ù¸∗ú¸ãä éçµJäÞ¶   
  Let   = 1 G$ µ1 + ¶     
Under the sharp null that the means are the same between the treatment arms and the 
control arms for all cells, a(¤|¤~(0,1, the therefore a(¤~(0,1. 
  na(¤|∆Õ =  n ∑ £ù¸∗ ∆Õù¸ú¸ãä∑ £ù¸∗ú¸ãä |∆Õ 
                          =   ∑ Ànó £ù¸∗∑ £ù¸∗ú¸ãä |∆Õõn Ö∆Õû¸|∆Õ×Æh¹1      Assume ∆Õ⊥ ]∗ 
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                          =   ∑ Øb∆Õ bOb1 nó ∑ £ù¸∗ú¸ãä∑ £ù¸∗ú¸ãä |∆Õõ 
                          =   ∑ Øb∆Õ bOb1 nó∑ ]û¸∗h¹1 õ 
Let / = nó∑ ]û¸∗h¹1 õ= ∑ íQ] + (` − Q]$ ïQ`ð _¥ä _$(hL¥äh¥ä17  
 SkËÌa¤(, a¤($Í = nÌa¤(a¤($Í = nÌn$óa(¤õ|∆ÕÍ 
                                                =  $/$n Ö∑ Øb∆Õ bOb1 $× 
n ïg Øb∆Õ bOb1 ð$	 = ØQl qg Øb∆Õ bOb1 s = g (Øb$Ob1 ØQlÌ∆Õ bÍ 
 = µ1 + ¶ G$ ∑ ï £∗³ ðOb1 ∙ 4 £³∗∑ £³∗â³ãä 5$ = µ1 + ¶ G$ ∑ £³∗â³ãä∑ £³∗â³ãä ç = µ1 + ¶ G$ ∑ £³∗â³ãä  
 ⇒  SkËÌa¤(, a¤($Í =  $ /$ µ1 + ¶ G$ ∑ £³∗â³ãä = /$ ∑ £³∗â³ãä ≜ ∗ 
 ⇒ Under Null: Ìa¤(, a¤($ÍM~ qµ00¶ , ï 1 ∗∗ 1 ðs 
Under alternative distribution: 
a(¤|¤~(  ∑ Øû¸∆û¸h¹1 , 1 , and ∆û¸~Q__lk,~(Ç, /È$, / = OLhOL. 
nóa(¤õ = nÌnóa(¤|¤õÍ = n   ∑ £ù¸∗ ∆ù¸ú¸ãä∑ £ù¸∗ú¸ãä  =  Çn  ∑ £ù¸
∗ú¸ãä∑ £ù¸∗ú¸ãä   Assume ∆Õ⊥ ]∗ 
                   =  Çn q∑ ]û¸∗h¹1 s =  /Ç  where / = n q∑ ]û¸∗h¹1 s  
 
ØQlóa(¤õ = nÌØQlóa(¤|¤õÍ + ØQlÌnóa(¤|¤õÍ = 1 +  $ØQl ∑ £ù¸∗ ∆ù¸ú¸ãä∑ £ù¸∗ú¸ãä . 
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ØQl ∑ £ù¸∗ ∆ù¸ú¸ãä∑ £ù¸∗ú¸ãä  = ∑ ÀØQl  £ù¸
∗ ∆ù¸∑ £ù¸∗ú¸ãä Æh¹1 = ∑ 6n À7 £ù¸
∗ ∆ù¸∑ £ù¸∗ú¸ãä 8
$Æ −h¹1
n$  £ù¸∗ ∆ù¸∑ £ù¸∗ú¸ãä 9  
 
= ∑ :n  £ù¸∗ ç∑ £ù¸∗ú¸ãä 	 ∙ n Ö∆û¸$ × − n$  £ù¸∗∑ £ù¸∗ú¸ãä  ∙ n$ Ö∆û¸×;h¹1   
 
= ∑ :n  £ù¸∗ ç∑ £ù¸∗ú¸ãä 	 ∙ (Ç$ + /7È$ − 7n  £ù¸∗ ç∑ £ù¸∗ú¸ãä 	 − ØQl  £ù¸∗∑ £ù¸∗ú¸ãä 8 ∙ Ç$;h¹1   
= ∑ : n  £ù¸∗ ç∑ £ù¸∗ú¸ãä 	 ∙ Ç$ + n  £ù¸∗ ç∑ £ù¸∗ú¸ãä 	 /7È$ − n  £ù¸∗ ç∑ £ù¸∗ú¸ãä 	 Ç$ + ØQl  £ù¸∗∑ £ù¸∗ú¸ãä  ∙ Ç$;h¹1   
 = ∑ :n  £ù¸∗ ç∑ £ù¸∗ú¸ãä 	 /7È$ + ØQl  £ù¸∗∑ £ù¸∗ú¸ãä  ∙ Ç$;h¹1   
= /7È$n ∑ £ù¸∗ çú¸ãä∑ £ù¸∗ú¸ãä 	 + Ç$ 7ØQl  ∑ £ù¸∗ú¸ãä∑ £ù¸∗ú¸ãä 8 = /7È$n ∑ £ù¸
∗ çú¸ãä∑ £ù¸∗ú¸ãä 	 +
Ç$ ïØQl q∑ ]û¸∗h¹1 sð  
= /7È$n ∑ £ù¸∗ çú¸ãä∑ £ù¸∗ú¸ãä 	 + Ç$ ïn Ö∑ ]û¸∗h¹1 × − n$ q∑ ]û¸∗h¹1 sð  
= /7È$n ∑ £ù¸∗ çú¸ãä∑ £ù¸∗ú¸ãä 	 + Ç$(`(_] + _$]$ − /$  
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 = n ∑ £ù¸∗ çú¸ãä∑ £ù¸∗ú¸ãä 	 = ∑ pÌ¥ä£äçJ(hL¥ä£ççÍ¥ä£äJ(hL¥ä£ç ïQ`ð _¥ä _$(hL¥äth¥ä17   
ØQlóa(¤õ = 1 +  $ó/7È$
 + Ç$(`(_] + _$]$ − /$õ. 
nÌa¤(a¤($Í = nÌn$óa(¤õ|∆ÕÍ =  $/$n Ö∑ Øb∆Õ bOb1 $×  
n Ö∑ Øb∆Õ bOb1 $× = ØQlÌ∑ Øb∆Õ bOb1 Í + n$Ì∑ Øb∆Õ bOb1 Í = ∑ Øb$ØQló∆Õ bõOb1 +
∑ ØbnÌ∆Õ bÍOb1 $  
                                = µ1 + ¶ G$ ∑ ï £∗³ ðOb1 ∙ 4 £³∗∑ £³∗â³ãä 5$ + (∑ Øb∆bOb1 $  
                                = µ1 + ¶ G$ ∑ £³∗â³ãä + Ç$  
⇒ nÌa¤(a¤($Í =  $ /$ q µ1 + ¶ G$ ∑ £³∗â³ãä + Ç$s = ç∑ £³∗â³ãä +  $/$Ç$  
nÌa¤(ÍnÌa¤($Í = n$óa(¤õ =  $/$Ç$  
⇒  SkËÌa¤(, a¤($Í = nÌa¤(a¤($Í − nÌa¤(ÍnÌa¤($Í  
                                                     = ç∑ £³∗â³ãä +  $/$Ç$ −  $/$Ç$ = ∗ 
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APPENDIX C FORMULATION OF POWER CALCULATION FOR UNEQUAL 
PATIENT SAMPLE SIZE CASE (POISSON DISTRIBUTION) 
L cells, within each cell there are ]∗ control units and l]∗ treatment units.  
Assume ,~_k\yyk](ñ, ]∗ = , + 1 shifted Possion (or truncated) 
∆b : true mean difference for cell \, \ = 1,2, … , 2, and ∆Õ b: the difference of sample means. G$: constant variance within each cell. 
For ` randomly selected cells, ¤ = (¤, ¤$, … , ¤h 
  a(¤ = ∑ øù¸∆Õù¸ú¸ãäø¥µ∑ øù¸∆Õù¸ú¸ãä ¶ where Øû¸ = £ù¸∗∑ £ù¸∗ú¸ãä  
ØQl µ∑ Øû¸∆Õû¸h¹1 ¶ = ∑ Øû$¸ ØQl µ∆Õû¸¶ =h¹1 ∑ Øû$¸ éç£ù¸∗ µ1 + ¶h¹1 =
∑ üù¸∗ çþçüù¸∗ µJäÞ¶ú¸ãäµ∑ £ù¸∗ú¸ãä ¶ç  =
éçµJäÞ¶ ∑ £ù¸∗ú¸ãä
µ∑ £ù¸∗ú¸ãä ¶ ç = é
çµJäÞ¶∑ £ù¸∗ú¸ãä     
a(¤ = ∑
üù¸∗∑ üù¸∗ú¸ãä ∆Õù¸ú¸ãä
ý þçµääÞ¶∑ üù¸∗ú¸ãä
= ∑ £ù¸∗ ∆Õù¸ú¸ãä∑ £ù¸∗ú¸ãä éçµJäÞ¶   
  Let   = 1 G$ µ1 + ¶     
Under the sharp null that the means are the same between the treatment arms and the 
control arms for all cells, a(¤|¤~(0,1, the therefore a(¤~(0,1. 
  na(¤|∆Õ =  n ∑ £ù¸∗ ∆Õù¸ú¸ãä∑ £ù¸∗ú¸ãä |∆Õ 
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                          =   ∑ Ànó £ù¸∗∑ £ù¸∗ú¸ãä |∆Õõn Ö∆Õû¸|∆Õ×Æh¹1      Assume ∆Õ⊥ ]∗ 
                          =   ∑ Øb∆Õ bOb1 nó ∑ £ù¸∗ú¸ãä∑ £ù¸∗ú¸ãä |∆Õõ 
                          =   ∑ Øb∆Õ bOb1 nó∑ ]û¸∗h¹1 õ 
Since ,û¸~Ûk\yyk](ñ, then v ≜ ∑ ,û¸h¹1 ~Ûk\yyk](`ñ 
/ ≜ n q∑ ]û¸∗h¹1 s = nÌív + `Í = ∑ ív + ` ! L17  (Can be calculated by Monte 
Carlo Method) 
 SkËÌa¤(, a¤($Í = nÌa¤(a¤($Í = nÌn$óa(¤õ|∆ÕÍ 
                                                =  $/$n Ö∑ Øb∆Õ bOb1 $× 
n ïg Øb∆Õ bOb1 ð$	 = ØQl qg Øb∆Õ bOb1 s = g (Øb$Ob1 ØQlÌ∆Õ bÍ 
 = µ1 + ¶ G$ ∑ ï £∗³ ðOb1 ∙ 4 £³∗∑ £³∗â³ãä 5$ = µ1 + ¶ G$ ∑ £³∗â³ãä∑ £³∗â³ãä ç = µ1 + ¶ G$ ∑ £³∗â³ãä  
 ⇒  SkËÌa¤(, a¤($Í =  $ /$ µ1 + ¶ G$ ∑ £³∗â³ãä = /$ ∑ £³∗â³ãä ≜ ∗ 
 ⇒ Under Null: Ìa¤(, a¤($ÍM~ qµ00¶ , ï 1 ∗∗ 1 ðs 
a(¤|¤~(  ∑ Øû¸∆û¸h¹1 , 1 , and ∆û¸~Q__lk,~(Ç, /7È$, /7 = OLhOL. 
nóa(¤õ = nÌnóa(¤|¤õÍ = n   ∑ £ù¸∗ ∆ù¸ú¸ãä∑ £ù¸∗ú¸ãä  =  Çn  ∑ £ù¸
∗ú¸ãä∑ £ù¸∗ú¸ãä   Assume ∆Õ⊥ ]∗ 
                   =  Çn q∑ ]û¸∗h¹1 s =  /Ç  where / = n q∑ ]û¸∗h¹1 s  
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ØQlóa(¤õ = nÌØQlóa(¤|¤õÍ + ØQlÌnóa(¤|¤õÍ = 1 +  $ØQl ∑ £ù¸∗ ∆ù¸ú¸ãä∑ £ù¸∗ú¸ãä . 
ØQl ∑ £ù¸∗ ∆ù¸ú¸ãä∑ £ù¸∗ú¸ãä  = ∑ ÀØQl  £ù¸
∗ ∆ù¸∑ £ù¸∗ú¸ãä Æh¹1 = ∑ 6n À7 £ù¸
∗ ∆ù¸∑ £ù¸∗ú¸ãä 8
$Æ −h¹1
n$  £ù¸∗ ∆ù¸∑ £ù¸∗ú¸ãä 9  
 
= ∑ :n  £ù¸∗ ç∑ £ù¸∗ú¸ãä 	 ∙ n Ö∆û¸$ × − n$  £ù¸∗∑ £ù¸∗ú¸ãä  ∙ n$ Ö∆û¸×;h¹1   
 
= ∑ :n  £ù¸∗ ç∑ £ù¸∗ú¸ãä 	 ∙ (Ç$ + /7È$ − 7n  £ù¸∗ ç∑ £ù¸∗ú¸ãä 	 − ØQl  £ù¸∗∑ £ù¸∗ú¸ãä 8 ∙ Ç$;h¹1   
= ∑ : n  £ù¸∗ ç∑ £ù¸∗ú¸ãä 	 ∙ Ç$ + n  £ù¸∗ ç∑ £ù¸∗ú¸ãä 	 /7È$ − n  £ù¸∗ ç∑ £ù¸∗ú¸ãä 	 Ç$ + ØQl  £ù¸∗∑ £ù¸∗ú¸ãä  ∙ Ç$;h¹1   
 = ∑ :n  £ù¸∗ ç∑ £ù¸∗ú¸ãä 	 /7È$ + ØQl  £ù¸∗∑ £ù¸∗ú¸ãä  ∙ Ç$;h¹1   
= /7È$n ∑ £ù¸∗ çú¸ãä∑ £ù¸∗ú¸ãä 	 + Ç$ 7ØQl  ∑ £ù¸∗ú¸ãä∑ £ù¸∗ú¸ãä 8 = /7È$n ∑ £ù¸
∗ çú¸ãä∑ £ù¸∗ú¸ãä 	 +
Ç$ ïØQl q∑ ]û¸∗h¹1 sð  
= /7È$n ∑ £ù¸∗ çú¸ãä∑ £ù¸∗ú¸ãä 	 + Ç$ ïn Ö∑ ]û¸∗h¹1 × − n$ q∑ ]û¸∗h¹1 sð  
  79
= /7È$n ∑ £ù¸∗ çú¸ãä∑ £ù¸∗ú¸ãä 	 + Ç$ ïnóv + ` õ − n$ q∑ ]û¸∗h¹1 sð  
= /7È$n ∑ £ù¸∗ çú¸ãä∑ £ù¸∗ú¸ãä 	 + Ç$(`ñ + ` − /$  

 = n ∑ £ù¸∗ çú¸ãä∑ £ù¸∗ú¸ãä 	 Can be calculated by Monte Carlo 
ØQlóa(¤õ = 1 +  $ó/7È$
 + Ç$(`ñ + ` − /$õ. 
nÌa¤(a¤($Í = nÌn$óa(¤õ|∆ÕÍ =  $/$n Ö∑ Øb∆Õ bOb1 $×  
  
n Ö∑ Øb∆Õ bOb1 $× = ØQlÌ∑ Øb∆Õ bOb1 Í + n$Ì∑ Øb∆Õ bOb1 Í = ∑ Øb$ØQló∆Õ bõOb1 +
∑ ØbnÌ∆Õ bÍOb1 $  
                                = µ1 + ¶ G$ ∑ ï £∗³ ðOb1 ∙ 4 £³∗∑ £³∗â³ãä 5$ + (∑ Øb∆bOb1 $  
                                = µ1 + ¶ G$ ∑ £³∗â³ãä + Ç$  
⇒ nÌa¤(a¤($Í =  $ /$ q µ1 + ¶ G$ ∑ £³∗â³ãä + Ç$s = ç∑ £³∗â³ãä +  $/$Ç$  
nÌa¤(ÍnÌa¤($Í = n$óa(¤õ =  $/$Ç$  
⇒  SkËÌa¤(, a¤($Í = nÌa¤(a¤($Í − nÌa¤(ÍnÌa¤($Í  
                                                     = ç∑ £³∗â³ãä +  $/$Ç$ −  $/$Ç$ = ∗ 
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APPENDIX D PARTIAL LIKELIHOOD ESTIMATION 
Partial Likelihood (no tied events): 
Data: T j ,δ j , X j( ), j = 1,2,...,n. 
 Ordered event times: t1 < t2 <L < tD . 
R(ti ) :  All individuals still under study at a time just prior to ti .  
X(i ) :  Covariate of the individual whose failure time is ti .  
P the particular person in R(ti ) died at ti | one death at ti( ) = exp[β
T X(i )]
exp[β T X j ]j∈R(ti )∑
 
LL β( ) = X(i )T β
i=1
D
∑ − log
i=1
D
∑ exp(βT X j )j∈R(ti )∑   
Ul β( ) = x(i )l
i=1
D
∑ −
z jl exp(β T X j )j∈R(ti )∑
exp(β T X j )j∈R(ti )∑i=1
D
∑  
In our case: 
P the particular person in R(ti ) died at ti | one death at ti( ) =
exp[β beA(i ) ]
z j exp[β beAj ]{ }j∈R(ti )∑








zi
exp[β nbA(i )]
1− z j( )exp[β nbA j ]{ }j∈R(ti )∑








1−zi
 
 
LL β be,β nb( ) = zi *β beA(i ) − zi log z j exp[β beAj ]{ }j∈R(ti )∑( ){
i=1
D
∑
+(1− zi )*β nbA(i ) − (1− zi )log 1− z j( )exp[β nbAj ]{ }j∈R(ti )∑( )}  
 
 
U β be( ) = zi A(i ) − z j A j exp[β
beA j ] j∈R(ti )∑
z j exp[β beA j ]{ }j∈R(ti )∑







i=1
D
∑  0 
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U β nb( ) = 1− zi( ) A(i ) − 1− z j( ) Aj exp[β
nbAj ]

j∈R(ti )∑
1− z j( )exp[β nbAj ]{ }j∈R(ti )∑








i=1
D
∑  0  
 
The likelihood: 
g j = f (T j | Aj )
δ jS(T j | Aj )
1−δ j
= λ(T j | Aj )S(T j | Aj ) 
δ j
S(T j | Aj )
1−δ j
= λ(T j | Aj ) 
δ j
S(T j | Aj ) = λ0 (T j )exp(β beA j ) 
δ j
S0 (T j )
exp(β beA j )
 
h j = λ0 (T j )exp(β nb Aj ) 
δ j
S0 (T j )
exp(βnbA j )
 
Breslow’s estimator of H0 (T j ) = λ0(ti )ti≤Tj∑  
And S0 (T j ) = 1− λ0 (ti )[ ]ti≤Tj∑  
⇒ Lβ (λ0 (t)) = g jz j hj1−z j
j=1
n∏
= λ0 (T j )exp(β beAj ) 
δ j
S0(T j )
exp(βbeAj ){ }z j
j=1
n∏ ⋅ λ0 (T j )exp(β nbAj ) δ j S0 (T j )exp(β nbA j ){ }1−z j
= λ0 (T j )exp(β beAj ) 
δ j
exp −H0 (T j )exp(β beAj ) { }z j
j=1
n∏
⋅ λ0(T j )exp(β nbAj ) 
δ j
exp −H0 (T j )exp(β nbAj ) { }1−z j
= λ0 (T j )exp(z jβ beA j + (1− z j )β nbAj ) 
δ j
j=1
n∏
⋅exp −H0 (T j ) z j exp(β beAj ) + (1− z j )exp(β nbAj )  
 
 
 
Let di  ziβ beAi + (1− zi )β nb Ai  and e j  z j exp(β beAj ) + (1− z j )exp(β nbAj ) 
  82
 
Lβ (λ0 (t )) = λ0 (ti )exp(di )
i=1
D∏




exp − I ti≤Tj{ }λ0 (ti )e j




i=1
D
∑
j=1
n
∑






= λ0 (ti )exp(di )
i=1
D∏




exp −λ0 (ti ) ej
j∈R(ti )
∑
i=1
D
∑






= λ0 (ti )exp(di )
constant
123
exp −λ0 (ti ) e j
j∈R(ti )
∑













i=1
D∏
∝ λ0 (ti )exp −λ0 (ti ) ej
j∈R(ti )
∑













i=1
D∏
 
 
LLβ λ0 (t)( ) = log λ0 (ti )( ) − λ0 (ti ) e j
j∈R(ti )
∑






i=1
D
∑ ⇒
∂
∂λ0 (ti )
=
1
λ0 (ti )
− e j
j∈R(ti )
∑ = 0  
⇒ λˆ0 (t) =
1
e j
j∈R(ti )
∑
= z j exp(β beAj )+ (1− z j )exp(β nbAj )
j∈R(ti )
∑






−1
 
 
 83
BIBLIOGRAPHY 
1. Sørensen, T.I., Which patients may be harmed by good treatments? The Lancet 
1996. 348(9024): p. 351-352. 
2. R., S., Patient heterogeneity in clinical trials. Cancer Treatment Reports, 1980. 
64: p. 405-410. 
3. Kravitz, R.L., Duan, Naihua and Braslow, Joel . , Evidence‐Based Medicine, 
Heterogeneity of Treatment Effects, and the Trouble with Averages. Milbank 
Quarterly 2004. 82(4): p. 661-687. 
4. Peto, R., Statistical aspects of cancer trials. Treatment of Cancer 1982: p. 867-
871. 
5. Lagakos, S.W., The challenge of subgroup analyses-reporting without distorting. 
New England Journal of Medicine, 2006. 354(16): p. 1667-1669. 
6. Rothwell, P.M., Subgroup analysis in randomised controlled trials: importance, 
indications, and interpretation. The Lancet. 365(9454): p. 176-186. 
7. Rui Wang, S.L., James Ware, David Hunter, and Jeffrey Drazen., Statistics in 
medicine—reporting of subgroup analyses in clinical trials. New England Journal 
of Medicine, 2007. 357(21): p. 2189-2194. 
8. Gail, M., and Simon, R. , Testing for qualitative interactions between treatment 
effects and patient subsets. Biometrics, 1985. 41: p. 361-372. 
9. Piantadosi, S., and Gail, M., A comparison of the power of two tests for 
qualitative interactions. Statistics in Medicine, 1993. 12(13): p. 1239-1248. 
10. Li, J. and I.S. Chan, Detecting Qualitative Interactions in Clinical Trials: An 
Extension of Range Test. Journal of Biopharmaceutical Statistics, 2006. 16(6): p. 
831-841. 
11. Bayman, E.Ö., K. Chaloner, and M.K. Cowles., Detecting Qualitative 
Interactions: A Bayesian approach. Statistics in Medicine, 2010. 29(4): p. 455-
463. 
12. Gelber., M.B.a.R., Patterns of treatment effects in subsets of patients in clinical 
trials. Biostatistics, 2004. 5(3): p. 465-481. 
13. Wei Chen, D.G., Trivellore Raghunathan, Maxim Norkin, Daniel  Sargent, and 
Gerold Bepler., On Bayesian methods of exploring qualitative interactions for 
targeted treatment. Statistics in Medicine, 2012. 31(28): p. 3693-3707. 
14. Tian, L., Ash Alizadeh, Andrew Gentles, and Robert Tibshirani. , A simple 
method for detecting interactions between a treatment and a large number of 
covariates. arXiv preprint, 2012. 1212(2995). 
15. Foster, J., Taylor, J., and Ruberg, S., Subgroup identification from randomized 
clinical trial data. Statistics in Medicine, 2011. 30(24): p. 2867-2880. 
16. Dusseldorp, E.a.M., Iven Van., Qualitative interaction trees: a tool to identify 
qualitative treatment–subgroup interactions. Statistics in Medicine, 2014. 33(2): 
p. 219-237. 
17. Moss, A.J., et al., Prophylactic implantation of a defibrillator in patients with 
myocardial infarction and reduced ejection fraction. New England Journal of 
Medicine 2002. 346(12): p. 877-883. 
  84
18. Goldenberg, I., et al. , Risk stratification for primary implantation of a 
cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. 
Journal of the American College of Cardiology, 2008. 51(3): p. 288-296. 
19. Foster, J.C., Jeremy MG Taylor, and Stephen J. Ruberg., Subgroup identification 
from randomized clinical trial data. Statistics in Medicine, 2011. 30(24): p. 2867-
2880. 
20. Xu, Y., Yu, Menggang , Zhao, Ying‐Qi, Li, Quefeng, Wang, Sijian, and Shao, 
Jun., Regularized outcome weighted subgroup identification for differential 
treatment effects. Biometrics, 2015. 
21. Marks-Konczalik, J., Costa,Maria, Robertson, Jon, McKie, Elizabeth, Yang, 
Shuying , and Pascoe, Steven., A post-hoc subgroup analysis of data from a six 
month clinical trial comparing the efficacy and safety of losmapimod in 
moderate-severe COPD patients with ≤2% and >2% blood eosinophils. 
Respiratory Medicine, 2015. 109(7): p. 860-869. 
22. Schou, I.M., and C Marschner,  Ian., Methods for exploring treatment effect 
heterogeneity in subgroup analysis: an application to global clinical trials. 
Pharmaceutical statistics, 2015. 14(1): p. 44-55. 
23. Freedman, M.S., De Stefano, Nicola, Barkhof, Frederik, Polman, Chris H., Comi, 
Giancarlo, Uitdehaag, Bernard MJ, Casset-Semanaz, Florence  et al., Patient 
subgroup analyses of the treatment effect of subcutaneous interferon β-1a on 
development of multiple sclerosis in the randomized controlled REFLEX study. 
Journal of neurology, 2014. 261(3): p. 490-499. 
24. Berger, J.O., Wang, Xiaojing, and Shen, Lei., A Bayesian approach to subgroup 
identification. Journal of biopharmaceutical statistics, 2014. 24(1): p. 110-129. 
25. Farewell, V.T., The use of mixture models for the analysis of survival data with 
long-term survivors. Biometrics, 1982. 38: p. 1041-1046. 
26. Farewell, V.T., Mixture models in survival analysis: Are they worth the risk? 
Canadian Journal of Statistics, 1986. 14(3): p. 257-262. 
27. Kuk, A.Y., and Chen-Hsin Chen., A mixture model combining logistic regression 
with proportional hazards regression. Biometrika, 1992. 79(3): p. 531-541. 
28. Ng, S.K., and G. J. McLachlan., An EM‐based semi‐parametric mixture model 
approach to the regression analysis of competing‐risks data. Statistics in 
Medicine, 2003. 22(7): p. 1097-1111. 
29. Peng, Y., and Keith BG Dear., A  nonparametric mixture model for cure rate 
estimation. Biometrics, 2000. 56(1): p. 237-243. 
30. Corbière, F., et al., A penalized likelihood approach for mixture cure models. 
Statistics in Medicine, 2009. 28(3): p. 510-524. 
31. Shen, C., Jeong, Jaesik, Li, Xiaochun, Chen, Peng‐Sheng, Treatment Benefit and 
Treatment Harm Rate to Characterize Heterogeneity in Treatment Effect. 
Biometrics, 2013. 69(3): p. 724-731. 
  
CURRICULUM VITAE 
Lin H. Taft 
EDUCATION       Ph.D. in Biostatistics(Epidemiology minor)               August 2016 
                              Department of Biostatistics 
                              Indiana University, Indianapolis, IN           
                              M.S. in Statistics                                                               July 2010 
                              University of Minnesota, Duluth, MN          
                              B.S. in Applied Mathematics, and B.S. in Economics   July 2008 
                              Xiamen University, Xiamen, China          
WORK                  Principal Statistician                             September 2015 to present 
EXPERIENCE     GlaxoSmithKline, Upper Providence, PA 
                              Research Assistant                                      July 2013 to June 2015 
                              School of Medicine, Indiana University, Indianapolis, IN 
Graduate Assistant                                August 2011 to June 2013 
Statistical Computer Lab/Statistical Consulting Center,  
  IUPUI, Indianapolis, IN 
PUBLICATIONS [1] Doytchinova, A., Patel, J., Zhou, S., Chen, L. S., Lin, H., Shen,      
C., ... & Chen,  P. S. (2015). Subcutaneous nerve activity and 
spontaneous ventricular arrhythmias in ambulatory dogs. Heart 
Rhythm, 12(3), 612-620. 
 
 [2] Hellman, Y., Malik, A. S., Lin, H., Shen, C., Wang, I. W., 
Wozniak, T. C., ... & Hadi, A. (2014). B-Type Natriuretic Peptide 
  
Guided Therapy and Length of Hospital Stay Post Left Ventricular 
Assist Device Implantation. ASAIO Journal, 61(2), 156-160. 
 
[3] Steenburg, S. D., Petersen, M. J., Shen, C., & Lin, H. (2014). 
Multi-detector CT of blunt mesenteric injuries: usefulness of imaging 
findings for predicting surgically significant bowel 
injuries. Abdominal imaging, 40(5), 1026-1033. 
 
[4] Balint, B. J., Steenburg, S. D., Lin, H., Shen, C., Steele, J. L., & 
Gunderman, R. B. (2014). Do Telephone Call Interruptions Have an 
Impact on Radiology Resident Diagnostic Accuracy? Academic 
radiology 21(12), 1623-1628. 
 
[5] Whitesell, R., Steenburg, S., Shen, C., & Lin, H. Facial Fracture 
in the Setting of Whole Body Computed Tomography for Trauma 
Incidence and Clinical Predictors. American Journal of 
Roentgenology, 205(1), W4-W10. 
 
